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ABSTRACT 
 Transfusion of blood products is a common medical procedure, and maintaining 
adequate blood supply depends on the unpaid donation of a small share of the general 
population. The absence of pre-donation testing for iron status allows many donors with 
iron deficiency to donate blood. This dissertation seeks to enhance our understanding of 
the causes of iron deficiency among blood donors, the resultant symptoms, and the likely 
effectiveness of alternate strategies for reducing the risk of iron deficiency.  
 In Study 1, we used data from the REDS-II RISE prospective cohort study, over a 
2-year follow-up period, to evaluate whether higher levels of dietary iron protect against 
incident iron deficiency in blood donors. Responses to a brief checklist of consumption of 
animal proteins were combined into an Iron Composite Score weighted for iron content 
and reported frequency. We found that donors reporting the lowest levels of iron 
consumption were more likely to develop advanced iron depletion during follow-up.  
In Study 2, we performed an analysis of observational data from the STRIDE 
study, a randomized trial, to evaluate whether improvements in iron status were 
associated with improvements in reported fatigue levels. Using linear regression, we 
found that many donors had sizable changes in both reported levels of fatigue and in 
		 viii 
measures of iron status, but neither iron status nor changes in iron status was associated 
with fatigue at the end of 20–24 months follow-up.  
In Study 3, we conducted a simulation study to evaluate the range of outcomes of 
different strategies that might be adopted by blood centers to reduce the prevalence of 
iron depletion in blood donors. Using inputs primarily from the REDS-II program, we 
simulated approaches that extended the minimum interval between donations, that 
promoted use of iron supplementation by blood donors, and that performed ferritin 
testing to determine donor iron stores and extended the donation interval to those with 
iron depletion. Only extending the current 8-week interval to 26 weeks approached a 
reduction by half of the proportion of blood donors who were iron deficient, but the 
estimated impact on blood supply was a 21% drop in blood availability. Those 
interventions impacting supply less were also less effective in reducing iron depletion.  
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CHAPTER ONE: INTRODUCTION 
 
Concern for iron depletion in blood donors has existed for at least four decades. 
Shortly after development of the ferritin test in the 1970s, its application to blood donors 
followed quickly. Ferritin is a protein that represents the primary storage form of iron in 
the body. While most of the iron in humans is incorporated into hemoglobin molecules 
inside red blood cells and most of the body’s ferritin is found in the liver, the amount of 
ferritin in plasma is an indirect measure of the amount of iron in the body. Early studies 
by Simon and Finch showed that repeated blood donation was associated with low levels 
of ferritin.31, 56 Multiple workshops and other scientific forums have addressed the issue 
of iron depletion, and recent studies have firmly established it as a common occurrence in 
blood donors and helped clarify the risk factors.13, 14, 33, 44, 53  
Addressing the problem of iron depletion among blood donors has been 
challenging for an array of reasons. One reason relates to an imperfect correlation 
between levels of hemoglobin and levels of iron, and to reliance on a pre-donation 
eligibility screen that uses donor hemoglobin as a proxy for iron status. One can have low 
hemoglobin—called anemia—without having low iron, and one can have low iron 
without having anemia. In earlier periods of more prevalent nutritional insufficiency, lack 
of dietary iron was the most common cause of anemia, and today low iron is responsible 
for most anemia in a blood donor population. The total amount of a body’s iron drops 
considerably before it begins to alter hemoglobin synthesis, however. Thus, while the 
point-of-care hemoglobin test used in blood centers is helpful in preventing iron 
deficiency anemia, it is not very informative about reductions in iron that have yet to 
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affect hemoglobin production. 
Another challenge relates to the difficulty in teasing out whether any physiologic 
manifestations from iron deficiency result from the attendant anemia found in most iron 
deficient populations studied. There is growing evidence that high-performance athletes 
might be impacted by low iron in the absence of anemia, but most research on fatigue, 
cognitive impairment, and other conditions is conducted in subjects with both conditions. 
Oral and intravenous administration of exogenous iron can correct both low iron and low 
hemoglobin, so a concerted effort is required to discover and characterize health 
outcomes associated with iron depletion without anemia. 
Finally, identifiable solutions exist that would reduce the frequency of iron 
depletion in blood donors, but none is without its own complications. Most simply, 
donors could be required to wait longer between donations to allow sufficient time for 
absorption of the 250mg or so of iron lost in a typical donation. The current 8-week 
minimum interval in the US is based on studies from the 1940s measuring regeneration of 
hemoglobin in young, healthy, male subjects.32 The kinetics of iron recovery in a 
demographically diverse donor population indicate that many donors require a much 
longer period. Naturally, any restriction on donation eligibility has a corresponding effect 
on blood collections, as a disproportionate share of blood is donated by a relatively small 
population of high-commitment donors. Accelerating recovery of iron following donation 
through encouragement of iron supplementation is another approach. That exogenous 
iron accelerates return to normal hemoglobin and iron levels is well known.57 Reticence 
to directly provide iron pills derives from concern that it may be contraindicated in some 
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donors (susceptible to over-accumulation of iron, called hereditary hemochromatosis) or 
that it could mask a gastrointestinal bleed or other serious conditions in others. Efforts to 
encourage use of supplemental iron can be and are joined with exhortations to coordinate 
and communicate with a donor’s primary care physician. These less direct measures may 
also be less effective in prompting donors to appropriately use supplemental iron.  The 
issue is almost entirely unstudied.  
 The results that follow address iron depletion among blood donors from three 
different perspectives. We seek to better understand causes of iron depletion, and whether 
in the context of serial donation the impact of dietary iron remains relevant. In another 
population that experienced meaningful changes in iron status during the observation 
period, we aim to determine whether improvements or decrements in iron levels are 
associated with related improvements or declines in reported fatigue. Finally, we apply 
newly-available data to a simulation of mitigation strategies for iron depletion. The 
tension between the imperatives of sustaining a robust blood supply and protecting 
donors against iron depletion is unavoidable. Rigorous evaluations of the range of likely 
outcomes and the resulting tradeoffs may help inform better solutions. 
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CHAPTER TWO: DIETARY HEME IRON CONSUMPTION AND BLOOD 
DONOR IRON STATUS 
 
Introduction 
 Iron balance is tightly regulated by the body to avoid both iron deficiency and 
over-accumulation. Iron contributes to vital cellular functions, but is toxic in excess and 
can cause organ damage. There is no active excretory mechanism, so iron homeostasis is 
maintained by continuous recycling of body iron and limiting intestinal uptake based on 
signals relating to iron levels17 and to active red cell production.39 Under normal 
conditions, physiologic loss among males is about 1 mg/day, and 1.5 mg/day among non-
pregnant premenopausal women.23 The proportion of consumed iron that is absorbed to 
maintain homeostasis varies but is estimated at 6% in adult males and 13% in adult 
females.23 Determinants of absorption include the amount of body iron, the rate of 
erythropoiesis, the amount and type of dietary iron, and dietary compounds that enhance 
or inhibit iron absorption.23  Up to 90% of dietary iron comes from nonheme iron, found 
in plants and other foods, but heme iron, derived from animal protein, is much more 
readily absorbed and is less susceptible to inhibition by other dietary factors.37  
In contrast to equilibrium conditions, blood donation is an acute hemorrhage 
event that removes roughly 250 mg of iron in 10 to 15 minutes.12 Numerous studies have 
shown that consumption of iron supplements is associated with lower risk of iron 
deficiency in repeat blood donors,11,15,34 but blood centers are ambivalent about directly 
providing iron tablets to donors out of concern that it may mask occult gastrointestinal 
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(GI) blood loss, amongst other concerns.9 Indeed, blood centers rarely provide iron pills 
other than on an experimental basis,9,68 though there is growing support for blood centers’ 
directly providing iron supplements to frequent donors.2,22,43  Instead, the near-universal 
recommendation to blood donors has long been to eat iron-rich foods, and even this 
communication is often restricted to donors with low hemoglobin.28  
Despite the frequency of high-iron diet messaging, little evidence exists to support 
the notion that dietary iron maintains blood donor iron status and fitness for donation. In 
a recently published study of both new and frequent donors, none of several animal 
proteins was on its own associated with protection against exhaustion of iron stores in 
multivariate analysis.13 Among Danish blood donors,53 more frequent consumption of 
meat (unspecified, but presumably pork and beef) was associated with increased iron 
stores, albeit with modest effect size, and was protective against iron deficiency for both 
males and premenopausal females. However, because this study was cross-sectional, 
temporality could not be established and the possibility of reverse causation (i.e. 
increased consumption of meat motivated by low iron stores) remains. Finally, a cross-
sectional study among Australian blood donors found no correlation between reported 
total dietary iron intake and iron status.10  
Overall, the literature on the relationship between dietary iron and iron status 
among blood donors is scant, and the evidence for an effect not very compelling. Only 
one of the studies to date evaluated the effects of a composite measure of total dietary 
iron consumption10 but the study’s size was small and it found no association. To address 
the gaps in the current literature, we assessed the association between dietary heme iron, 
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analyzed as a composite measure, and iron deficiency using longitudinal data. We 
hypothesize that relatively high levels of dietary heme iron will be protective against 
incident iron depletion. If a summary measure of heme iron derived from a brief 
instrument is associated with iron status in repeat donors, an empirical basis for blood 
center recommendations on dietary iron could be established. To the contrary, blood 
centers may choose to retire the recommendation on dietary iron, to provide supplemental 
iron to donors, or to restrict donation frequency by donors unable to tolerate or unwilling 
to take iron. In either case, the outcome potentially affects millions of U.S. blood donors 
who donate on a regular basis. 
Methods 
Study population 
 
The data for this study come from the RISE Study (REDS-II Iron Status 
Evaluation), a prospective cohort study designed to estimate the occurrence of and risk 
factors for iron deficiency in blood donors. RISE was conducted by six blood centers 
participating in the REDS-II program (Retrovirus and Donor Evaluation Study-II) 
sponsored by the National Heart, Lung, and Blood Institute (NHLBI), and has been 
described elsewhere.13,14 Briefly, RISE enrolled 2,425 blood donors into 4 cohorts 
characterized by sex and recent donation history. First-time or “reactivated” (FT/RA) 
male and female donors had not donated blood in the prior two years; frequent repeat 
female donors made at least 2 donations and frequent repeat male donors made at least 3 
donations in the year prior to enrollment. Informed consent was obtained at enrollment 
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for the following: 1) additional testing of iron status during 15–24 months of follow-up, 
2) completion of self-administered questionnaires, and 3) connection of study data to the 
routine, operational blood center data on donor visits and donation information during the 
study period. Completion of enrollment was defined as successful whole blood or double-
red cell donation by the subject. The RISE study was approved by the respective IRBs of 
all six blood centers, the coordinating center, and the central laboratory.  Of the 888 first-
time/reactivated donors and 1537 frequent donors enrolled in RISE, the current study 
reports on 1414 (58%) who were iron replete at enrollment. While indicators of iron 
status may vary by gender and age, iron replete was defined in this study as the absence 
of either intermediate or advanced iron depletion, defined below. 
Data Collection 
Assessment of exposure 
 
Study participants completed a self-administered questionnaire that included an 
abbreviated checklist adapted from the 124-item Diet History Questionnaire (DHQ).48 
Participants reported how frequently over the prior twelve months they consumed each of 
8 items in the checklist, representing various categories of animal proteins. The DHQ 
from which the wording on frequency and response option was derived had been 
previously validated against other food frequency questionnaires (FFQs) using a series of 
season-specific 24-hour recall phone interviews, indicating strong correlation between 
12-month DHQ inquiries and 24-hour recalls for most nutrient categories, including 
estimated median daily intake of iron.61  We derived an Iron Composite Score (ICS)  
from responses to the checklist, weighted for frequency of consumption and iron content 
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for each item  based on the USDA national nutrient database (see Appendix A2.1 for 
details).62 Because its accuracy in estimating heme iron consumption is limited by the 
lack of data collected on quantity or portion size, we divided the ICS into tertiles to 
indicate relative quantities of heme iron consumption. We did not assess non-heme iron. 
Though nonheme iron constitutes approximately 90% of dietary iron,37 heme iron is 
much more readily absorbed and also drives absorption of nonheme iron.  
Assessment of outcome 
Plasma samples were prepared from whole blood collected from donation visits at 
enrollment and during follow-up for hematological and iron assays. Two measures of 
iron depletion were assessed: 1) Iron Deficient Erythropoiesis (IDE), an intermediate 
stage of iron depletion in donors, defined as the upper 2.5% of the distribution of 
log(soluble transferrin receptor/ferritin) in the FT/RA male cohort at enrollment 
(representing a cohort expected to have no recent blood loss); and 2) Absent Iron Stores 
(AIS), which was defined as a ferritin < 12 ng/mL and represents complete depletion of 
storage iron.13 Biomarkers for iron status were measured at enrollment and at final visit 
15–24 months later for all donors completing the study and for select donors at routine 
donation visits during the intervening months (interim visits). 
Assessment of covariates 
Information on other covariates of interest was self-reported or extracted from 
operational databases, including donation frequency and the interval since the last 
donation. Donation frequency and interval are important determinants of iron status in 
blood donors, and were updated as dynamic variables at each donation visit. Also 
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assessed were donor demographic variables, including age, gender, race/ethnicity, and 
weight. Subject use of supplemental iron, whether in the form of multivitamins 
containing iron or separate iron supplements, was captured via the questionnaires 
completed at enrollment and final visits. 
Statistical Analysis 
We first describe the overall RISE cohort by donor demographic and donation 
frequency related covariates, and include stratification by iron status at enrollment to 
indicate the share of donors within each covariate level that was iron replete at enrollment 
and eligible for the analysis reported here. The primary exposure of ICS is characterized 
by medians/IQR of reported values (in mg of iron) within each tertile. The number of 
donors at baseline, and their subsequent time on study, donation behavior, and outcome 
assessments are reported for each tertile. 
Our primary outcome was incident iron depletion, representing progression from 
an iron replete state at enrollment to either intermediate (IDE) or complete (AIS) 
depletion of storage iron. Because ascertainment of iron status was performed selectively 
for visits during the 15- to 24-month interim period follow-up and by design on all 
donors at final visit, results were reviewed separately by post-enrollment visit type to 
evaluate whether sampling decisions may have induced selection bias. Specifically, 
ferritin and soluble transferrin receptor (sTfR) testing were preferentially performed on 
interim visits for donors in the first-time male and female donor cohorts (samples from 
69–78% visits were tested) and in the frequent female donor cohort.  This represents 
1,540 visits with iron outcomes assayed out of 4,474 interim visits by donors studied 
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here. Because iron assays were performed on samples from all final visits by design, 
missing data are negligible, representing an occasional hemolyzed sample or broken 
specimen tube. The prevalence of IDE and AIS measured at interim period and at final 
visits was calculated overall, and stratified by tertiles of ICS and other covariates.  
Bivariate and multivariate analyses were conducted on the association between 
Iron Composite Score and iron status using two combinations of follow-up visits (from 
interim period and from final visit). One approach uses all available data from interim 
and final visits, which, based on the patterns of iron assessment, represents a greater 
share of first-time donors and frequent female donors than frequent male donors. The 
second approach is restricted to final visit outcomes only, for which outcome assessment 
was available for 98% of subjects (696 of 710 completing the study). Covariates assessed 
as potential confounders were demographic and behavioral variables related to the Iron 
Composite Score and identified in the literature to be related to iron status in blood 
donors and.13,14,53 Final models included covariates that were associated with both ICS 
and iron status or that were strong predictors of iron status even if they did not confound 
the association between ICS and iron status.  
Donation frequency is reported as a dynamic variable updated at each donation 
visit to reflect number of donated red cell products over the trailing 24-month period, and 
was grouped into categories representing light (1–3 donations), moderate (4–6), and 
heavy donation intensity (7+ donations in prior two years). Recency intervals were 
derived from dates in the operational database and are collapsed into broad categories for 
ease of interpretation (< 12 weeks, 12–15.9, 16–23.9, ≥ 24 weeks). Weight (< 150 lbs, 
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150–174, 175–199, ≥ 200 lbs) and age (< 30 years, 30–39, 40–49, 50–59, ≥ 60) were 
modeled as categorical variables, and use of supplemental iron was grouped as ever 
taking (at study enrollment, conclusion, or both) or never taking (not at beginning or 
end). Dairy was modeled separately as a potential inhibitor of iron consumption, 
dichotomized as ≤ 4 times per week vs > 4 times. Adjacent categories of several 
covariates were collapsed together in multivariate analysis to ensure model convergence 
for models limited to final visits and for models stratified by potential effect modifiers. 
We assessed effect modification on the ratio scale by running models stratified by sex, 
given that estimated proportion of dietary iron absorbed varies by sex.23 Modification by 
baseline ferritin values was also assessed since levels of body iron contribute to 
regulation of intestinal uptake of iron.17 Ferritin level at baseline was dichotomized as 26 
to 50 vs > 50 ng/mL, with 50 ng/mL representing the level below which accelerated 
recovery of ferritin following donation was observed in subjects provided exogenous iron 
in a recent study.18  
Risk ratios (RR) and 95% confidence intervals (CI) were estimated using 
modified Poisson regression with Generalized Estimating Equations with robust error 
variance.70 The first approach using all available interim and final visits included 
potentially multiple visits for a given subject, accounted for using an exchangeable 
correlation matrix in the modified Poisson regression models. Subjects who did not 
complete the food checklist at enrollment were excluded from analysis. Subjects missing 
ferritin values at final visit were included in the analysis if they had an interim visit with 
ferritin results, but otherwise were excluded from the analysis. The only covariate with an 
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appreciable amount of missing data was supplemental iron consumption (18 % at 
baseline and 20% at final visit), for which many donors who reported taking a 
multivitamin were uncertain whether it contained iron. The analysis was run excluding 
those visits and then repeated with those visits classified as “unknown” and repeated 
again re-classifying the unknown visits to non-usage of iron (based on unpublished data 
of our research group) after confirming no material change in parameter estimates. The 
possibility that the effect of ICS might vary with time was assessed by adding an 
interaction term between months on study and ICS tertile. SAS version 9.4 was used to 
perform all analyses. 
Results 
Of the 2,425 donors enrolled in RISE, 1414 (58%) were iron replete at enrollment 
(Table 2.1), having neither Iron Deficient Erythropoiesis (IDE) nor Absent Iron Stores 
(AIS). The iron replete cohort studied here was drawn almost equally from those with no 
prior donations (n=769) and from those who met the definition of “frequent repeat” donor 
to qualify for RISE (n=645). Males and females were included in relatively equal 
proportions, and the age distribution reflects the well-recognized commitment of adult 
blood donors in middle and older age groups. Caucasian	individuals	were	more	likely	than	other	racial	groups	to	be	included	in	the	cohort, similar to the RISE cohort and 
the donor population of the six centers conducting the RISE study. 
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 All RISE donors Iron Depleted (AIS or IDE) Iron Replete* 
All donors 2425 1011 42% 
1414 
58% 
Male 1175 384 33% 
791 
67% 
Female 1250 627 50% 
623 
50% 
Donations over prior 24 months at enrollment, by sex 
Male 415 12 3% 
403 
97% 0 donations 
1–3 78 23 29% 
55 
71% 
4–6 247 120 49% 
127 
51% 
7–9 271 131 48% 
140 
52% 
≥10 164 98 60% 
66 
40% 
Female 
488 122 25% 
366 
75% 0 donations 
1–3 224 127 57% 
97 
43% 
4–6 312 209 67% 
103 
33% 
7–9 181 135 75% 
46 
25% 
≥10 45 34 76% 
11 
24% 
Age 
≤ 20 194 67 35% 
127 
65% 
20–29 282 109 39% 
173 
61% 
30–39 340 137 40% 
203 
60% 
40–49 497 206 41% 
291 
59% 
50–59 626 276 44% 
350 
56% 
≥60 486 216 44% 
270 
56% 
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Race / ethnicity 
White 2111 897 42% 
1214 
58% 
Asian 76 21 28% 
55 
72% 
Black 116 48 41% 
68 
59% 
Hispanic 76 31 41% 
45 
59% 
Other 28 11 38% 
18 
62% 
Blood center 
A 436 161 37% 
275 
63% 
B 390 161 41% 
229 
59% 
C 376 150 40% 
226 
60% 
D 392 155 40% 
237 
60% 
E 415 199 48% 
216 
52% 
F 416 185 44% 
231 
56% 
Taking supplemental iron 
No 1047 421 40% 
626 
60% 
Yes 954 420 44% 
534 
56% 
Uncertain 424 166 39% 
258 
61% 
Weight 
< 150 lbs 595 304 51% 
291 
49% 
150 – 199 lbs 1149 485 42% 
664 
58% 
 ≥ 200 lbs 659 213 32% 
446 
68% 
Table 2.1. Donors enrolled in RISE and iron status at enrollment. 
* Study cohort reported here 
AIS = Absent Iron Stores (ferritin < 12 ng/mL) 
IDE = Iron Deficient Erythropoiesis (log(sTfR/ferritin) ≥ 2.07 
RISE = REDS-II Donor Iron Status Evaluation Study 
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Nearly all of the iron-replete donors (1406 of 1414) completed the FFQ 
administered at enrollment into RISE (Table 2.2 and Figure 2.1). The median ICS for the 
lowest tertile was 7.2 mg weekly (interquartile range (IQR): 5.5–9.3), and the median 
ICS of the middle and highest tertiles was 13.1 and 22.2, respectively. The ICS did not 
differ greatly at study enrollment by gender, or by prior donation history (Figure 2.2). 
The greatest contributor to the ICS was beef, representing 37% of the overall iron 
content, with another 25% added by protein in eggs, followed by 21% from the combined 
category of lamb, pork, chicken and turkey. The remaining categories – clams, liver, 
oyster / mussels / shrimp / sardines, and other fish— all contributed minor amounts that 
together summed to 17% of reported iron intake. The relative contributions of iron by 
food categories also did not differ by gender or donation history at enrollment (data not 
shown). 	  
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Iron Composite Score at Enrollment (Med, IQR) 
 1st tertile 2nd tertile 3rd tertile All donors 
Enrollment (mg) 7.2 (5.5–9.3) 
13.1 
(11.6–14.4) 
22.2 
(17.6–24.0) 
13.0 
(9.3–17.6) 
 
Food items, average frequency of consumption in times per week (Med, IQR) 
Liver 0  (0,0) 
0 
(0,0) 
0 
(0,0.5) 
0 
(0,0) 
Beef 1 (0.5, 2) 
2 
(2, 3.5) 
3.5 
(2, 5.5) 
2 
(1, 3.5) 
Lamb, pork, 
chicken, turkey 
2 
(1, 3.5) 
3.5 
(2, 3.5) 
3.5 
(3.5, 5.5) 
3.5 
(2, 3.5) 
Clams 0 (0, 0.5) 
0 
(0, 0.5) 
0.5 
(0, 0.5) 
0 
(0, 0.5) 
Oysters, mussels, 
shrimp, sardines 
0.5 
(0, 0.5) 
0.5 
(0.5, 0.5) 
0.5 
(0.5, 0.5) 
0.5 
(0.5, 0.5) 
Other fish 0.5 (0.5, 1) 
1 
(0.5, 1) 
1 
(0.5, 2) 
1 
(0.5, 1) 
Eggs 1 (0.5, 1) 
1 
(1, 2) 
3.5 
(2, 3.5) 
1 
(1, 2) 
Dairy 5.5 (3.5, 7) 
7 
(3.5, 14) 
7 
(5.5, 14) 
7 
(3.5, 14) 
Table 2.2a. Reported heme iron consumption frequency for iron-replete subjects at baseline 
summarized by tertile of iron composite score (ICS). 
 
 1st tertile 2nd tertile 3rd tertile All donors 
Enrolled subjects (N) 466 471 469 1406 
Interim period visits (N) 1510 1528 1436 4474 
Interim visits with iron status 535 498 507 1540 
Subjects with final visit 232 244 234 710 
Median months on study, IQR 19 18–21 
19 
18–21 
19 
18–21 
19 
18–21 
Median number donations, IQR 6 4–9 
6 
4–8 
6 
4–8 
6 
4–8 
Table 2.2b. Study visits, follow-up, and donations by tertile of ICS. 
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Figure 2.1. Enrollment, eligibility, and evaluable visits for REDS-II RISE subjects  FT	=	First	Time;	RPT	=	Repeat;	IR	=	Iron	Replete;	FFQ	=	Food	Frequency	Questionnaire;	IV	=	Interim	Visits;	FV	=	Final	Visits	
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Figure 2.2. Iron Composite Score (mg of iron per week) by sex and donation status  
 
The 1,406 enrolled subjects who completed the FFQ at baseline remained on 
study for a median of 19 months (IQR 18 to 21 months) and donated an average of 6 
times during that period (IQR 4–8). Overall, there were 4474 visits between enrollment 
and the formal final visit, and 1540 of them had ferritin measurements. Just over half of 
the enrolled donors (710) remained in the study long enough to complete the final visit, 
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for which ferritin was universally assessed by design (2% loss due to sample 
unavailability). The multivariable models including both interim and final visits have 
nearly 2,200 observations, while those restricted to final visits only have 682 
observations. 
The development of iron deficiency was a common phenomenon as subjects 
continued donating over the following 15–24 months. By study end, more than one in 
four subjects had developed intermediate iron depletion (IDE), and nearly one in twelve 
had exhausted their iron stores altogether (AIS, Table 2.3). The study completion rate did 
not differ by tertile of ICS, nor did the number of donation visits made during the interim 
period. Altogether, about one third of all interim visit donations assessed iron status 
outcomes, with no difference by tertile (Table 2.2b). Iron status measured during interim 
visits showed slightly higher prevalence of AIS and IDE compared to final visits. 
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 Iron status at Interim Visits  
(n=1540) 
Iron status at Final Visit  
(n=696) 
 N IDE % AIS % N IDE % AIS % 
All donors 1540 34.5% 8.8% 696 28.2% 7.9% 
Iron Composite Score tertile 
Tertile 1 535 41.3% 14.6% 223 31.4% 13.5% 
Tertile 2 498 34.3% 6.2% 241 26.1% 5.0% 
Tertile 3 507 27.4% 5.1% 232 27.2% 5.6% 
Gender 
Female 965 44.5% 12.2% 297 37.7% 12.5% 
Male 575 17.7% 3.0% 399 21.1% 4.5% 
Age 
< 30 yrs 226 32.7% 10.6% 69 27.5% 11.6% 
30–39 204 29.4% 6.4% 60 36.7% 1.7% 
40–49 325 36.0% 8.9% 138 28.3% 10.1% 
50–59 446 36.1% 9.0% 213 27.2% 8.0% 
≥60 339 35.1% 8.6% 216 26.9% 6.9% 
Donations last 24 months 
1–3 donations 936 26.6% 5.9% 152 15.1% 4.6% 
4–6 donations 389 45.0% 14.1% 220 27.7% 9.1% 
7–9 donations 154 52.6% 13.0% 210 40.0% 10.5% 
≥10 donations 61 42.6% 8.2% 114 24.6% 5.3% 
Interval since prior donation 
Up to 12 weeks 699 47.1% 14.0% 205 49.8% 14.2% 
12 to 16 weeks 262 31.3% 7.6% 80 32.5% 7.5% 
16 to 24 weeks 305 23.0% 4.3% 169 21.3% 5.9% 
≥24 weeks 271 18.1% 1.1% 242 13.2% 4.1% 
Weight 
< 150 lbs 454 50.2% 16.7% 135 40.7% 16.3% 
150–175 lbs 381 34.1% 6.8% 173 31.2% 8.1% 
175–199 lbs 297 29.3% 7.4% 161 28.0% 6.2% 
≥200 lbs 408 21.1% 2.7% 225 18.7% 4.0% 
Iron supplementation 
Ever 750 33.9% 8.1% 339 24.5% 6.2% 
Never 350 34.0% 8.9% 215 32.6% 10.2% 
Uncertain 440 35.9% 9.8% 142 30.3% 8.5% 
Dairy consumption 
0 to 4 times / week 345 24.4% 7.5% 187 25.7% 8.0% 
5 to 7 times / week 692 37.7% 7.8% 312 27.6% 7.4% 
Twice daily or more 478 36.6% 10.3% 185 30.3% 8.7% 
Enrollment iron status 
Ferritin ≤ 50 ng/mL 640 53.9% 17.0% 398 34.4% 11.1% 
Ferritin > 50 ng/mL  900 20.7% 2.9% 298 19.8% 3.7% 
Table 2.3. Prevalence of iron depletion measured at interim and final visits. 
AIS = Absent Iron Stores (ferritin < 12 ng/mL) 
IDE = Iron Deficient Erythropoiesis (log(sTfR/ferritin) ≥ 2.07 
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In bivariate analysis using data from all visits, the Iron Composite Score was 
associated with intermediate (IDE) and complete (AIS) depletion of iron stores (Table 
2.4). While the estimated association between the middle tertile of ICS and iron status 
was modest, the lowest level stood out for elevated risk compared to the third tertile. 
Across all follow-up visits, 14% of subjects in Tertile 1 had AIS compared to about 5% 
in Tertile 3 (RR of 2.8, 95% CI 1.7, 4.6). The risk ratio for lowest compared to highest 
tertile for IDE was 1.4 (95% CI 1.1, 1.8).  In both univariate and multivariate analyses 
(reported below), the direction and magnitude of associations between tertile of ICS and 
AIS / IDE were similar for models including all follow-up visits and those including just 
final visits, indicating no evident selection bias from the selective iron testing from 
interim visits. For this reason, models reported here reflect those run on all follow-up 
visits, with model results using only the final visits available in Appendix A2.2. 
 
 Iron Deficient Erythropoiesis 
 
Absent Iron Stores 
Iron Composite Score (ICS) tertile Crude RR,  
95% CI 
Adjusted RR, 
95% CI 
Crude RR,  
95% CI 
Adjusted RR, 
95% CI 
Tertile 1 1.40 (1.12, 1.75) 
1.19 
(0.97, 1.45) 
2.77 
(1.69, 4.55) 
2.40 
(1.51, 3.81) 
Tertile 2 1.20 (0.95, 1.51) 
1.08 
(0.88, 1.33) 
1.20 
(0.67, 2.15) 
1.12 
(0.64, 1.97) 
Tertile 3 Ref Ref Ref Ref 
Sex     
Male Ref Ref Ref Ref 
Female 2.11 (1.74, 2.55) 
1.82 
(1.47, 2.24) 
3.44 
(2.18, 5.43) 
1.91 
(1.11, 3.30) 
Age group     
Age< 30 1.02 
(0.76, 1.37) 
1.38 
(1.08, 1.77) 
1.33 
(0.70, 2.51) 
1.78 
(1.04, 3.05) 
30–39 1.03 
(0.76, 1.39) 
1.33 
(1.03, 1.73) 
0.55 
(0.23, 1.32) 
0.69 
(0.32, 1.50) 
40–49 Ref Ref Ref Ref 
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50–59 
1.01 
(0.79, 1.29) 
0.95 
(0.77, 1.18) 
1.06 
(0.55, 2.04) 
0.79 
(0.50, 1.26) 
≥60 
0.99 
(0.76, 1.37) 
0.96 
(0.76, 1.20) 
0.99 
(0.53, 1.84) 
0.95 
(0.56, 1.61) 
Donation Frequency Prior 24 months    
1–3 Ref Ref Ref Ref 
4–6 
1.62 
(1.36, 1.94) 
1.64 
(1.38, 1.94) 
2.85 
(1.68, 4.85) 
2.39 
(1.55, 3.69) 
≥7 
2.02 
(1.64, 2.48) 
1.90 
(1.53, 2.36) 
3.00 
(1.74, 5.15) 
1.68 
(0.94, 2.98) 
Interval since prior donation     
Up to 12 weeks 2.50 
(2.02, 3.08) 
2.50 
(2.03, 3.08) 
5.21 
(2.69, 10.1) 
4.93 
(2.73, 8.89) 
12 to 16 weeks 
1.83 
(1.44, 2.32) 
1.80, 
(1.42, 2.28) 
3.56 
(1.69, 7.49) 
3.25 
(1.67, 6.31) 
16 to 24 weeks 
1.35 
(1.08, 1.68) 
1.39 
(1.11, 1.73) 
2.32 
(1.12, 4.81) 
2.42 
(1.27, 4.61) 
> 24 weeks Ref Ref Ref Ref 
Weight     
< 150 lbs 
1.60 
(1.26, 2.04) 
1.08 
(0.86, 1.36) 
2.49 
(1.46, 4.24) 
1.09 
(0.64, 1.87) 
150–174 
1.11 
(0.85, 1.45) 
1.04 
(0.82, 1.31) 
1.10 
(0.60, 2.01) 
0.81 
(0.47, 1.40) 
175–199 Ref Ref Ref Ref 
≥200 0.62 
(0.46, 0.84) 
0.72 
(0.54, 0.96) 
0.44 
(0.22, 0.89) 
0.56 
(0.29, 1.07) 
Use of supplemental iron      
Never take 
1.07 
(0.89, 1.28) 
1.37 
(1.17, 1.61) 
1.22 
(0.82, 1.81) 
2.01 
(1.42, 2.85) 
Ever take Ref Ref Ref Ref 
Dairy consumption     
0 to 4 times / week Ref Ref Ref Ref 
> 4 times / week 
1.31 
(1.05, 1.64) 
1.27 
(1.05, 1.45) 
1.01 
(0.64, 1.59) 
1.14 
(0.77, 1.70) 
Iron level at baseline     
Ferritin 26 to 50 ng/mL 
2.43 
(1.99, 2.96) 
1.57 
(1.28, 1.93) 
5.07 
(3.16, 8.12) 
2.91 
(1.73, 4.88) 
Ferritin > 50 ng/mL Ref Ref Ref Ref 
Table 2.4. Crude and adjusted associations between tertile of Iron Composite Score and 
iron status at all follow-up visits. 
AIS = Absent Iron Stores (ferritin < 12 ng/mL) 
IDE = Iron Deficient Erythropoiesis (log(sTfR/ferritin) ≥ 2.07 
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Demographic factors generally showed expected associations with iron status in 
bivariate analysis. Females had 2- to 3-fold higher risk for both IDE and AIS across all 
study visits, and risk for neither outcome varied meaningfully by age. Body mass, which 
correlates directly with total blood volume and, hence, the proportion of blood lost in a 
standard 525 mL donation, indicates a lower risk for donors with higher weights.  
Donation behavior showed the expected associations with risk for iron depletion. 
Subjects with 4 or more donations over the preceding 24 months had unadjusted risk for 
IDE or AIS 1.6 (95% CI 1.4, 1.9) to 3.0 times greater (95% CI 1.7, 5.2) than those with 
only 1 to 3 donations, respectively (Table 2.4). The importance of time in the recovery of 
iron following donation was evident in all comparisons. IDE was found in 18% of donors 
with donation visits 24 weeks or longer since their prior donation during interim visits, 
compared to 47% of donors who donated between 8 and 12 weeks following donation 
(Table 2.3).  Similar results were found across all visits, with unadjusted risk ratio for 
IDE of 2.5 (95% CI 2.0, 3.1) and for AIS of 5.2 (95% CI 2.7, 10.1) for those donating at 
8- to 12-week intervals compared to ≥ 24 weeks. 
Results from multivariate analysis were consistent with those from bivariate 
analysis (Table 2.4), indicating the lowest tertile of ICS to be associated with elevated 
risk for AIS compared to the highest tertile. During interim and final visits, those in the 
lowest tertile have greater than two-fold increased risk (RR=2.4; 95%CI 1.5, 3.8) 
compared to the highest tertile. At final visit the risk ratio is 2.3 (95%CI 1.0, 5.1), 
consistent with lack of selection bias from the interim period sampling frame (see 
Appendix A2.2). The association between tertile of ICS and iron status does not hold for 
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IDE in models from all follow-up visits or just the final visits, and the middle tertile is 
indistinct from the top tertile in all analyses.  
Female donors, those younger than age 30, and those who did not report use of 
supplemental iron at either study beginning or end all reflect higher risk for one or both 
of IDE and AIS. A modest inhibitory effect of dairy is indicated in the model predicting 
risk for IDE (RR 1.27, 95% CI 1.05, 1.45) but not in that for AIS. Adjusting for other 
covariates somewhat attenuates the apparent benefit of enrolling in RISE with a baseline 
ferritin ≥50 ng/mL (RR=2.9 for AIS, 95% CI 1.7, 4.9).  Higher trailing donation intensity 
(4 to 6, or 7+ donations in prior 24 months) is associated with higher risk for IDE, with 
risk ratios of 1.6 (95% CI 1.4, 1.9) and 1.9 (95% CI 1.5, 2.4) compared to donors giving 1 
to 3 donations, respectively. Similar patterns are seen for AIS. Recency of donation is a 
strong predictor of risk for IDE and AIS, with a clear gradient indicating risk for iron 
depletion lasts at least up to 24 weeks post donation. Those donating at intervals of 12 
weeks or less between donations have risk for iron depletion between 2.5 and nearly 5 
times greater than those waiting 24 weeks between donations, while those who wait 16–
24 weeks face intermediate risk (RR ranging from 1.4 to 2.4) compared with those 
donating at longer intervals. 
Discussion 
 The RISE study’s primary aim was to characterize the prevalence of and risk 
factors for iron depletion in new and established blood donors, and it found that repeated 
blood donation was a strong contributor to high prevalence of intermediate (≥50%) and 
advanced (≥20%) levels of iron depletion.13,14  This ancillary study sought to determine 
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whether dietary iron exerted a detectable effect on blood donor iron status or, to the 
contrary, the rate of absorption of ingested iron is overtaken by the loss of ≈ 250 mg of 
iron with each donated unit. The main finding here is that a composite measure 
summarizing the frequency of consumption and iron content of animal proteins is 
strongly predictive of incident iron depletion. In a cohort of subjects who were iron 
replete at enrollment, those in the lowest tertile of the Iron Composite Score were more 
than twice as likely to develop Absent Iron Stores (ferritin< 12 ng/mL) than subjects in 
the highest tertile. This effect held after controlling for several potential confounders of 
the association, including whether the subject reported taking supplemental iron at study 
beginning or conclusion.  
In contrast, the reported consumption of dietary iron showed at most an attenuated 
association with progression from iron replete to an intermediate level of iron depletion 
(Iron Deficient Erythropoiesis, or IDE). The unadjusted risk ratio of 1.4 (95% CI 1.1, 1.8) 
for those in the lowest tertile of ICS compared to those in the highest tertile diminished to 
1.2 (95% CI 1.0, 1.5) after adjusting for confounders. Other notable findings included a 
lesser degree of protection from supplemental iron and stronger evidence of an inhibitory 
effect of greater dairy consumption for intermediate as compared to advanced iron 
depletion. That fractional iron absorption increases at lower ferritin levels has been 
previously reported in the general nutrition literature24 and in healthy subjects,26 but this 
is the first study to document the effect in a large blood donor population.  
The few prior studies in blood donors that have evaluated dietary iron have been 
null or inconclusive, perhaps in part due to their cross-sectional design or analysis of food 
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items singly rather than combined.  One small study in Australia found no association 
between dietary iron intake and iron status, despite reported iron consumption that met 
estimated average requirements of the general population.10 A large Danish study found a 
modest level of protection (OR=0.92, 95% CI 0.88–0.92) against ferritin < 15 ng/mL for 
higher levels of meat consumption in men and pre-menopausal women, but not in post-
menopausal women.53 The subjects in the Danish study were being provided results of 
ferritin testing, so it is possible that dietary patterns were modified in response, an 
outcome consistent with the inverse association found between use of supplemental iron 
and lower iron stores. Finally, RISE also evaluated the relationship between the food 
categories reported here and iron status at enrollment, with none of the food categories on 
its own associated with either IDE or AIS.13 This re-analysis of RISE data using a 
composite score of dietary heme iron weighted for both reported frequency of 
consumption and estimated iron content offers a more robust assessment of the impact of 
ingested iron on donor iron status. While these results should be evaluated in other study 
populations, the findings reported here validate the message to blood donors that a diet 
rich in iron is helpful to maintaining fitness for blood donation. 
This study has a number of limitations. First, the food item checklist ascertained 
average weekly frequency of consumption and did not ask for information on portion 
size. This omission likely ensures that the estimated heme-iron intake is undercounted, a 
phenomenon observed in validation of the DHQ to another FFQ instrument that inquired 
only about frequency and not portion size.61 The recommended daily iron intake in the 
US is about 8 mg for adult men and post-menopausal women, and 18 mg for women of 
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childbearing years, and median reported intake is approximately 16 mg in males and 12 
in adult females of all ages,37 though > 90% of intake comes from non-heme sources. The 
median value of 13 mg heme iron weekly recorded in this study does not sharply diverge 
from the estimated levels of heme iron intake indicated from national surveys,51 
representing roughly two daily servings of chicken or equivalent protein or one of beef 
(see Table A.2.1). The fact that heme iron is more readily absorbed than non-heme iron, 
and that additionally heme iron facilitates absorption of non-heme iron23 suggests that 
grouping of subjects in a semi-quantitative fashion as done here may be a reasonable 
approach for assessing dietary iron intake and iron status in blood donors. One should 
note that modeling iron consumption as tertiles does not allow for identification of 
biologically relevant cutoffs. The lack of information on non-heme iron sources is likely 
of limited consequence given that heme iron is the primary driver of absorption of dietary 
iron. In either case, were such a checklist applied more broadly in the blood donation 
setting, it would have suitable utility and acceptance only to the degree it was kept simple 
and easy to complete quickly. 
Another limitation is the lack of information collected on several factors that can 
inhibit absorption of nonheme iron, including tannins in coffee and tea, polyphenols in 
certain vegetables, and phytate.23 However, calcium is considered an inhibitor of 
absorption of both heme and nonheme iron, and a listing for dairy products was included 
in our food item checklist. The median reported frequency for dairy products was daily 
across all subjects, with modest inhibitory effects of calcium observed in multivariate 
analyses of IDE but not AIS. This difference may relate to the greater fractional iron 
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absorption observed when iron stores are very low.23 Since calcium in the form of 
supplements was not captured in the questionnaire, the inhibitory effects of calcium may 
not be fully estimated. 
Another potential limitation is that the food item checklist was administered only 
once, at study enrollment. Hence, to the extent that the frequency of consumption of 
animal proteins might have changed during the study period, this study lacks the ability 
to document its occurrence. Theoretically, iron intake could be updated with each 
donation visit, so that changes could be recorded and taken into account in the analysis as 
a dynamic variable. However, validation of the DHQ shows it to be a reliable instrument 
of comparable accuracy to 24-recalls and food diaries, and it was designed to capture 
long-term intake over the previous year.61 Use of supplemental iron, by comparison, did 
not change for the large majority of subjects completing RISE, with 80% reporting the 
same use or non-use at study end as at enrollment. Whether dietary habits are as stable as 
use of supplements is speculative, but it is worth noting that the higher risk for AIS 
associated with ICS in the lowest tertile was found in multivariate analysis including all 
visits as well as only final visits.  
Additional strategies for protecting blood donors against iron depletion remain for 
blood centers.  They have been detailed in two industry bulletins1,2 and include limiting 
blood donation frequency, providing iron supplements to donors or otherwise 
encouraging their use, and performing ferritin testing of donors considered at risk for iron 
depletion, such as frequent donors and premenopausal women.  Evidence exists for the 
efficacy of all three options, but there are financial, logistical, or other considerations that 
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challenge implementation of them as well. The efficacy of exogenous iron in facilitating 
recovery of iron and hemoglobin has been underscored by the recent HEIRS study,40 but 
some blood donors suffer gastrointestinal distress or other adverse effects from iron 
supplements or simply wish not to take a daily pill. For these donors, recommendation of 
a diet with plenty of iron rich foods is a simple alternative, if indeed effective. This study 
suggests some minimal level of heme iron consumption above which these donors were 
capable of preventing progression from intermediate to complete iron depletion, 
consonant with the longstanding messaging to blood donors. Additional research is 
warranted to confirm this finding in other donor populations and to better quantify the 
relationship between iron intake and protection against iron depletion.	
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CHAPTER THREE: IRON STATUS AND SELF-REPORTED FATIGUE IN 
BLOOD DONORS 
Introduction 
Transfusion of blood is a frequently performed medical procedure, with more than 
11 million red cell units transfused annually.30 Roughly 70% of blood products are given 
by repeat blood donors, who face elevated risk for development of iron deficiency, often 
to the point where stored iron is exhausted.4,63 Blood centers have limited insight into the 
clinical manifestations of iron deficiency in donors.  The health questionnaire required 
prior to donation does not probe for symptoms of low iron. While measurement of donor 
hemoglobin is required by the FDA to qualify a donor for donation, measurement of 
donor iron status is not and it is rarely performed.  
 Thus, while many blood donors develop iron deficiency, the attendant clinical 
consequences are poorly documented. Fatigue has been associated with iron depletion in 
diverse clinical populations, but has been little studied in blood donor populations. 
Further, fatigue in the immediate post-donation period, thought to be due to loss of blood 
volume and the transient reduction in hemoglobin levels with recovery, is widely 
perceived by donors and confirmed by at least one study;47 however, fatigue that persists 
beyond the first two weeks or so post-donation and could be related to iron deficiency, 
has been little studied. Results of the few studies that have been done have been mixed, 
with inferences limited by cross-sectional design, lack of robust outcome ascertainment, 
lack of a control population and other methodological issues.47,49,52,65  
 The recently completed Strategies to Reduce Iron DEficiency (STRIDE) study 
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provides the opportunity for more rigorous assessment of the association between iron 
status and fatigue in blood donors.8,43 With longitudinal follow-up that includes 
biomarkers for iron status at each blood donation and assessment of fatigue at two time 
points, this analysis seeks to evaluate whether iron status is associated with fatigue at 
study inception or conclusion, and whether changes in iron status are related to changes 
in reported fatigue between those two time points. Given the high prevalence of iron 
depletion found in blood donor populations, establishment of a causal relationship with 
clinically relevant fatigue could lead to refinement of donor management practices for 
millions of donors annually. 
Methods 
Study population 
 We conducted an analysis of observational data from the STRIDE study. STRIDE 
was a randomized, blinded, placebo-controlled trial conducted at three blood centers to 
investigate alternate approaches for mitigating iron deficiency in blood donors. 
Enrollment and study procedures have been previously described.8,43  In brief, enrollment 
was limited to adult blood donors (≥ 18 years old) who were not taking supplemental 
iron, but who were willing to do so, and who met the study definition of “frequent” 
donors — 2 units of blood donated in the prior year for females and 3 units for males. 
Donors were randomized to an education intervention (2 groups) or a blinded iron 
supplementation treatment (3 groups) to prevent or reverse iron deficiency in blood 
donors. Arm 1 received a letter following each successful donation that provided 
information on their iron status, recommending they take supplemental iron or to delay 
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their next donation by 6 months if their iron was low. Arm 2 was a control group that 
received a thank-you letter following each donation that provided no information on iron 
status. Arms 3, 4 and 5 received 60 pills containing 38, 19, and 0 mg, respectively, of 
elemental iron following each successful whole blood donation, or 120 pills for a double-
unit donation.   
 Subjects were asked to continue donating at their regular frequency during the 
follow-up period of 24 months. Subjects in Arms 3, 4 and 5 were blinded to the iron 
content of their pills. Blood center research staff were blinded to treatment assignment 
with the exception of one staff member in one blood center who coordinated letter 
distribution to Arms 1 and 2 and pill mailings to the other 3 arms and who had no other 
interactions with donors.  This study reports on the enrollment cohort of 692 subjects and 
on 337 donors who completed a final visit and associated questionnaire. STRIDE was 
approved by institutional review boards at all participating institutions and the data 
coordinating center. 
Data collection 
 Information on behavioral, demographic, and other factors was collected by 
trained research staff at enrollment following study consent and again at final visits. Self-
administered questionnaires captured donor reports of conditions associated with iron 
depletion: restless legs syndrome, pica (craving and consumption of non-food items, 
often ice), and fatigue.  Fatigue was assessed with 11 questions adopted verbatim or 
slightly modified from four well-characterized fatigue instruments — FACIT-F, FACT-
An, FSS, and MAF (see Appendix A2.1).19,42,69  Most questions derive from FACIT-F, 
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which has been validated in clinical populations and the general population. All 11 
questions in their original instruments are presented on a Likert scale. Like FACIT-F, 
STRIDE used a 0 to 4 scale corresponding to responses “not at all” to “very much,” with 
reverse coding applied to negatively-worded questions. The range of the instrument is 0–
44, with 0 representing the lowest quality of life (QOL) and highest level of fatigue 
possible.  The Fatigue Score represents the mean of subject responses to the questionnaire 
and was calculated for the 99% of subjects who completed 8 or more of the 11 questions. 
The Fatigue Score is not normally distributed, showing considerable ceiling effects with a 
mean of 3.4 and 8% of the sample at the maximal value of 4 at enrollment. Fatigue Score 
was dichotomized with levels < 3.1 classified as representing fatigue, which corresponds 
roughly to the lowest quartile of scores in STRIDE subjects, and also roughly equivalent 
to the lowest quartile of the general US population as assessed by FACIT-F.19   
 Extra plasma samples were collected prior to donation at each donor visit during 
follow-up for hematological and iron assays. Biomarkers for iron status included ferritin, 
a measure of iron stores, and soluble transferrin receptor, a measure of iron levels in 
tissues. Both markers are used to derive the primary exposure of interest, body iron 
stores,25 which is a continuous measure of iron status that is normally distributed and is 
calculated as: 
 
Body Iron Stores = -[log10(soluble transferrin receptor * 1000/ferritin)-2.8229]/0.1207 
 
 Positive values represent positive iron balance (adequacy of iron in tissues and 
presence of storage iron) while negative values represent negative iron balance, including 
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diminished or depleted iron stores and iron deficits in the tissues. 
 Alternate measures of iron depletion were also assessed, including two 
dichotomous measures: 1) Iron Deficient Erythropoiesis (IDE), an intermediate stage of 
iron depletion in donors, calculated as a value of log(soluble transferrin receptor/ferritin) 
≥ 2.07, (as defined in the REDS-II RISE study;13 and 2) Absent Iron Stores (AIS) defined 
as ferritin < 12 ng/mL and representing complete depletion of storage iron. Venous 
hemoglobin was also measured for each visit via complete blood counts (CBCs) 
performed on blood center hematology analyzers, as previously described.8 Establishing 
whether fatigue is attributable to low iron or to low hemoglobin (anemia), or the co-
occurrence of both (iron deficiency anemia, IDA) requires attention to both parameters. 
While blood centers qualified blood donors for donation using a uniform minimum 
hemoglobin of 12.5 g/dL cutoff during the STRIDE study period (subsequently raised to 
13.0 g/dL in males in May 2016), we defined anemia for this analysis on the basis of 
population distributions reported by the CDC.23 Accordingly, male donors with a 
hemoglobin value < 13.5 or female donors with a hemoglobin < 12.0 g/dL were classified 
as having anemia. Data from donation visits and outcomes (donation of a single or double 
unit of red cells) were extracted from blood center operational databases. 
Statistical analysis 
 Our objective was to evaluate the effect of iron levels in blood donors on fatigue 
and of clinically meaningful changes in fatigue by conducting an observational cohort 
analysis of data collected as part of the randomized trial. We first characterize the entire 
cohort by iron/hematological status, fatigue measures, and other covariates at enrollment, 
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overall and stratified by whether they completed the study.  Though our primary 
objective was to assess the association between changes in iron status with reported 
fatigue over time, we also performed multivariate analyses of fatigue in the entire cohort 
at study enrollment and at study conclusion in those completing STRIDE. Both analyses 
used modified Poisson regression with generalized estimating equations (GEE) in order 
to estimate risk ratios rather than odds ratios, 70 with fatigue dichotomized as roughly the 
lowest quartile of Fatigue Scores. 
 After characterizing changes in body iron stores and in Fatigue Score over the 
course of the study, we perform multivariable linear regression to model the effect of 
changes in iron status on the primary outcome, change in Fatigue Score from baseline to 
study completion 20 to 24 months later. To attempt to control for potential selection bias 
due to loss to follow-up (44%), multivariate analysis was repeated with inverse 
probability of censoring weighting in order to create a pseudopopulation with the aim of 
providing an unbiased estimate of the effect of changes in iron on changes in Fatigue 
Score.36  Modified Poisson regression with GEE used both enrollment and subsequent 
interim visits during follow-up in the analysis to predict whether each subject completed 
the study, with candidate variables including group assignment, demographic factors, and 
changes in iron status and hemoglobin levels during the study. Use of interim visit data 
allowed for assessment of whether improvements in iron stores or hemoglobin levels 
predicted completion of the study, expanding the number of evaluable observations from 
692 to more than 3800.  Because anemia is an independent predictor of fatigue in the 
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absence of iron deficiency, final models were run with and without measures of 
hemoglobin levels to assess for potential bias in effects.  
 
Results 
 As previously described,8 the prevalence of iron depletion among STRIDE donors 
at enrollment was very high, with nearly two-thirds having ferritin < 26 ng/mL and one in 
four having ferritin < 12 ng/mL, or Absent Iron Stores (Table 3.1). Fewer donors were 
classified as anemic according to CDC criteria for venous hemoglobin levels determined 
on the collected blood (12%), undoubtedly owing to qualification for donation (and 
enrollment on the study) on the basis of minimum fingerstick screening hemoglobin 
levels. The completion rate of 57% was lower than originally projected (approximately 
80%), and varied most notably across treatment assignment. Seventy percent or more of 
subjects receiving the education letter (group 1) or the control letter (group 2) completed 
STRIDE, but completion rates in the three pill arms ranged from 38% (group 5, placebo 
pill) to 55% (group 3, 38mg of iron).  Males were more likely to complete the study than 
females (60% vs. 46%), and slightly higher completion rates are evident for donors who 
were anemic at baseline (61% vs 56%) and for those with absent iron stores (64% vs. 53–
56%). 
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Category All Subjects* 
(N=692) 
Completed study** 
(N=393) 
Did not 
complete** 
(N=299) 
Group Assignment     
1 (letter w/ iron status) 137 96 (70%) 41 (30%) 
2 (control letter) 139 105 (76%) 34 (24%) 
3 (38 mg iron pill) 139 76 (55%) 63 (45%) 
4 (19 mg iron pill) 139 63 (45%) 76 (55%) 
5 (placebo pill) 138 53 (38%) 85 (62%) 
Gender (N, %)    
Female 342 183 (46%) 159 (54%) 
Male 350 210 (60%) 140 (40%) 
    
Age (mean, SD) 53.2 (13.4) 54.0 (12.8) 52.0 (14.2) 
< 30 55 (8%) 23 (42%) 32 (58%) 
30–39 58 (8%) 32 (55%) 26 (44%) 
40–49 111 (16%) 63 (57%) 48 (43%) 
50–59 230 (33%) 130 (57%) 100 (43%) 
≥60 238 (34%) 145 (61%) 93 (39%) 
    
Weight (mean, SD) 186 (40) 185 (38) 188 (42) 
< 150 lbs 118 (17%) 68 (58%) 50 (42%) 
150 – 174 lbs 168 (25%) 95 (57%) 73 (43%) 
175 – 199 lbs 165 (24%) 95 (58%) 70 (42%) 
≥200 lbs 226 (33%) 129 (57%) 97 (43%) 
Baseline lab values    
Hemoglobin (g/dl)  
(mean, SD) 
14.0 (1.3) 14.0 (1.3) 14.0 (1.3) 
Anemia at baseline 83 (12%) 51 (61%) 32 (39%) 
No anemia at baseline 605 (88%) 341 (56%) 264 (44%) 
    
Ferritin (ng/ml)  
(median, IQR) 
19 (12–34) 19 (11–33) 20 (13–35) 
Ferritin ≥ 26 ng/ml  248 (36%) 138 (56%) 110 (44%) 
Ferritin 12 to 25 ng/ml 275 (40%) 147 (53%) 128 (47%) 
Ferritin < 12 ng/ml  169 (24%) 108 (64%) 61 (36%) 
    
Body iron stores baseline 
(mg/kg) (mean, SD) 
3.1 (3.5) 3.0 (3.6) 3.4 (3.5) 
    
Fatigue Score at baseline  
(median, IQR) 
3.55 
(3.18 – 3.73) 
3.55 
(3.18 – 3.82) 
3.45 
(3.09 – 3.73) 
Fatigue at baseline 166 (24%) 91 (55%) 75 (45%) 
No fatigue at baseline 524 (76%) 300 (57%) 224 (43%) 
Table 3.1. Characterization of STRIDE subjects at enrollment and association with study 
completion. 
* Values shown represent N (column %) unless indicated otherwise 
** Values shown represent N (row %) unless indicated otherwise 
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 The presence of fatigue at enrollment did not differ by randomization arm, as 
expected, but females and donors aged 60 years or older were 60% more likely to have 
fatigue compared with males and donors aged 40–49 years (Table 3.2, Figure 3.1). 
Subjects who were anemic at baseline were also more likely to have fatigue (RR 1.56; 
95% CI: 1.06–2.29). In contrast, neither body iron stores (RR 0.99; 95% CI: 0.95–1.04) 
nor other indicators of low iron including AIS (RR 1.01; 95% CI: 0.66–1.55) and IDE 
(RR 1.07; 95% CI: 0.78–1.48) were associated with fatigue at enrollment controlling for 
other factors.  
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Category 
Fatigue at 
enrollment 
Unadjusted RR 
(95CI)* 
Adjusted RR  
(95CI)* 
All donors (N=692) 166 (24%)   
Group Assignment     
1 (letter w/ iron status) 35 (26%) 1.23 (0.79, 1.91) 1.15 (0.75, 1.78) 
2 (control letter) 40 (29%) 1.43 (0.94, 2.17) 1.37 (0.91, 2.05) 
3 (38 mg iron pill) 32 (23%) 1.10 (0.70, 1.73) 0.98 (0.63, 1.52) 
4 (19 mg iron pill) 30 (22%) 1.03 (0.65, 1.63) 0.97 (0.62, 1.52) 
5 (placebo pill) 29 (21%) Ref Ref 
Gender    
Female 94 (28%) 1.36 (1.04, 1.79) 1.63  (1.18, 2.27) 
Male 72 (21%) Ref Ref 
Age    
< 30 12 (22%) 1.10 (0.59, 2.05) 1.18  (0.63, 2.21) 
30–39 11 (19%) 0.94 (0.49, 1.80) 0.96  (0.51, 1.81) 
40–49 22 (20%) Ref Ref 
50–59 50 (22%) 1.08 (0.69, 1.69) 1.16  (0.75, 1.79) 
60+ 71 (30%) 1.47 (0.96, 2.25) 1.59  (1.04, 2.44) 
Weight    
< 150 lbs 24 (20%) 0.86 (0.55, 1.35) 0.69 (0.43, 1.09) 
150 – 174 lbs 39 (23%) 0.98 (0.67, 1.45) 0.88 (0.59, 1.30) 
175 – 199 lbs 39 (24%) Ref Ref 
200 or more lbs 60 (27%) 1.13 (0.80, 1.61) 1.32  (0.92, 1.88) 
Baseline lab values    
Anemia at baseline 30 (34%) 1.51 (1.09, 2.11) 1.56  (1.06, 2.29) 
No anemia at baseline 136 (23%) Ref Ref 
    Body iron stores at baseline  
(per mg/kg), linear term  0.98 (0.94, 1.01) Not included** 
    Ferritin ≥ 26 ng/ml  56 (23%) Ref Ref 
Ferritin 12 to 25 ng/ml 66  
(24%) 
1.11 
(0.81, 1.52) 
1.07 
(0.78, 1.48) 
Ferritin < 12 ng/ml  44 (26%) 1.16 (0.82, 1.65) 1.01 (0.66, 1.55) 
    Number donations prior 24 
months, linear term  0.97 (0.92, 1.02) Not included** 
    < 4 donations 28 (26%) Ref Ref 
4 to 6 donations 62 (24%) 0.95 (0.64, 1.40) 0.91 (0.61, 1.37) 
7 to 9 donations 59 (28%) 1.12 (0.75, 1.65) 1.04 (0.68, 1.57) 
10 to 12 donations 17 (15%) 0.61 (0.35, 1.05) 0.63 (0.35, 1.13) 
Table 3.2. Predictors of fatigue at study enrollment. 
*Fatigue defined as Fatigue Score < 3.1 on scale of 0 to 4 (≈ lowest quartile of distribution)  
RR = Risk ratio 
** Variables excluded from multivariable model to ensure model convergence. 
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Figure 3.1. Distribution of mean Fatigue Score at enrollment by sex. 
 Of the 393 subjects completing STRIDE, 46 did not return a questionnaire, and 10 
others were missing lab results, so we report on 337 (86% of those completing, 49% of 
initial cohort) with complete data at study conclusion. Over the 20–24 months of 
observation, greater changes were evident in body iron stores than in Fatigue Scores 
(Figure 3.2, Figure A.3.1a) or the proportion of subjects with Fatigue Score < 3.1. Table 
3.3 shows a modest average gain for all donors of 1 mg body iron stores per kg of body 
weight (SD 3.5), representing a gain of approximately 33% over the enrollment body iron 
stores average of 2.9 mg/kg. The changes in iron status varied widely across treatment 
groups, as expected, with those in both control arms experiencing a decrement of 0.5 g/kg 
compared to gains of 2.2 to 2.6 mg/kg in those being distributed iron pills. With the 
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average weight of 77 kg for females and 92 kg for male at enrollment, this represents a 
range of 38 mg loss to 200 mg gain in women, and a range of 46 mg loss to 239 mg gain 
in men. This difference is equivalent to the iron content of a full unit of blood.12 The 
improvement in body iron stores varied even more by baseline ferritin, with those having 
ferritin < 12 ng/mL at enrollment experiencing a gain of 3.3 mg/kg versus a loss of 1.0 
mg/kg in the group beginning the study with ferritin ≥ 26 ng/mL. 
 
Figure 3.2. Changes in Fatigue Score and body iron (mg/kg) measured at final visit. 
 
 Neither initial ferritin levels, nor treatment arm, however, was associated with a 
meaningful change in fatigue score at study completion (Table 3.3). The same 
observation holds true for sex, age, and weight. Across all subjects, the average change in 
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Fatigue Score was 0.0 (SD 0.5). The only factor associated with a sizable change in 
bivariate analysis was whether fatigue was present at baseline. Those who were not 
classified as having fatigue at enrollment experienced a decrease in Fatigue Score of 0.1 
on average, versus a gain of 0.2 in those who were classified as having fatigue at 
enrollment, a difference of 0.6 SD overall. Nonetheless, those with fatigue at enrollment 
were still considerably more likely to have fatigue at study completion than those without 
(68% vs 15%), indicating that the improvements seen were of insufficient size and 
breadth to reverse fatigue for many subjects. The proportion of subjects classified as 
having fatigue at study end did not differ by group assignment or by starting ferritin 
levels, the two factors reflecting the greatest changes in body iron stores during the study. 
Hence, bivariate analysis provided little support for an association between changes in 
body iron stores and changes in self-reported fatigue.
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  Study Enrollment Study Completion (20–24m later) 
 N Body Iron 
Mean (SD) 
Fatigue Score 
Med (IQR) 
 
% Fatigue 
Δ Body 
Iron 
Δ Fatigue 
Score 
% 
Fatigue 
Change in 
% Fatigue 
All donors 337 2.9 (3.6) 3.55 (3.18–3.82) 22% 1.0 (3.5) 0.0 (0.5) 26% 4% 
         
Group Assignment          
1 (letter w/ iron status) 82 3.3 (3.7) 3.55 (3.18–3.73) 22% 1.4 (3.1) -0.1 (0.5) 27% 5% 
2 (control letter) 93 3.3 (3.8) 3.55 (3.09–3.82) 27% -0.5 (3.3) -0.1 (0.5) 34% 7% 
3 (38 mg iron pill) 66 2.7 (3.5) 3.55 (3.27–3.73) 20% 2.2 (3.5) 0.0 (0.5) 26% 6% 
4 (19 mg iron pill) 51 2.0 (3.3) 3.55 (3.18–3.82) 20% 2.6 (3.0) 0.0 (0.3) 20% 0% 
5 (placebo pill) 45 2.5 (3.6) 3.55 (3.18–3.82) 20% -0.5 (3.7) -0.1 (0.5) 18% -2% 
         
Gender (N, %)         
Female 161 1.9 (3.3) 3.45 (3.09–3.64) 25% 1.2 (3.8) 0.0 (0.5) 32% 7% 
Male 176 3.8 (3.7) 3.64 (3.27–3.82) 19% 0.8 (3.2) 0.0 (0.4) 22% 3% 
         
Age (years)         
< 30 15 1.5 (3.7) 3.55 (3.00–3.64) 33% 1.7 (3.2) 0.0 (0.5) 33% 0% 
30–39 25 1.6 (4.4) 3.73 (3.27–3.91) 20% 1.7 (3.6) 0.0 (0.4) 12% -8% 
40–49 54 3.0 (3.4) 3.55 (3.27–3.82) 15% 0.3 (3.1) -0.1 (0.4) 28% 13% 
50–59 112 3.0 (3.8) 3.55 (3.18–3.82) 21% 0.9 (3.7) 0.0 (0.4) 26% 5% 
≥60 131 3.2 (3.4) 3.50 (3.09–3.73) 25% 1.0 (3.6) 0.0 (0.5) 28% 3% 
          
Weight          
< 150 lbs 60 2.2 (3.1) 3.55 (3.24–3.73) 20% 1.6 (3.6) 0.0 (0.5) 20% 0% 
150 – 174 lbs 80 1.8 (3.8) 3.55 (3.18–3.73) 20% 1.6 (3.9) -0.1 (0.5) 26% 6% 
175 – 199 lbs 84 2.9 (3.4) 3.55 (3.27–3.82) 20% 0.5 (3.5) -0.1 (0.5) 26% 6% 
≥200 lbs 108 3.9 (3.7) 3.46 (3.09–.3.82) 28% 0.5 (3.1) 0.0 (0.4) 30% 2% 
         
Baseline lab values         
Anemia at baseline 45 0.3 (4.3) 3.55 (3.18–3.73) 31% 2.1 (4.2) 0.0 (0.6) 27% -4% 
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No anemia at baseline 291 3.3 (3.4) 3.45 (3.00–3.82) 21% 0.8 (3.4) 0.0 (0.4) 26% 5% 
         
Ferritin ≥ 26 ng/ml  116 6.6 (1.9) 3.55 (3.18–3.82) 21% -1.0 (2.5) -0.1 (0.5) 28% 7% 
Ferritin 12 – 25 ng/ml 124 2.8 (1.3) 3.55 (3.18–3.82) 23% 1.1 (3.3) 0.0 (0.5) 25% 2% 
Ferritin < 12 ng/ml  97 -1.5 (1.8) 3.55 (3.18–3.73) 23% 3.3 (3.5) 0.0 (0.4) 27% 4% 
         
Fatigue at baseline 75 2.4 (3.2) 2.82 (2.20–3.00) NA 1.3 (3.7) 0.2 (0.6) 68% NA 
No fatigue at baseline 262 3.0 (3.7) 3.64 (3.45–3.82) NA 0.9 (3.5) -0.1 (0.4) 15% NA 
Table 3.3. Body Iron Stores, Fatigue Score and Fatigue at Baseline, and Change in Body Iron Stores, Fatigue Score and Fatigue at 
Study Completion in Subjects Completing Study. 
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 Multivariate analysis did not alter this conclusion (Table 3.4). Neither 
demographic variables, nor body mass or treatment assignment was associated with 
changes in Fatigue Score. Similarly, laboratory parameters at baseline and their changes 
subsequent to enrollment showed no relationship with the observed changes in Fatigue 
Score. Controlling for other factors, a 1-unit change in body iron stores was associated 
with essentially unchanged Fatigue Scores (0.01 change, 95%CI: -0.01, 0.03), and even a 
change of 1 SD body iron stores (3.5 mg/kg) may not be clinically meaningful. Changes 
in hemoglobin levels (0.015 per g/dL change in Hb; 95% CI -0.039, 0.069), and whether 
one began the study anemic or with low ferritin, also showed no association with changes 
to Fatigue Scores. As with bivariate analysis, multivariate analysis pointed to only fatigue 
at enrollment as an independent predictor of change in Fatigue Score, showing a gain of 
0.36 (95%CI: 0.21, 0.51). Reduced models were run for the dichotomous outcome fatigue 
to ensure model convergence, and again baseline fatigue (RR 4.6; 95%CI: 3.27, 6.32) 
was the strongest predictor of fatigue status at study end. Female gender was also 
associated with fatigue at the end of STRIDE, albeit with an effect size somewhat 
attenuated compared to that at study inception (RR 1.37 compared to males, 95%CI: 
1.06, 1.79).   
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Category N = 337 Change in  
Fatigue Score+ 
(95CI)* 
Fatigue at Final 
Visit++ 
(RR, 95CI)* 
Group Assignment     
1 (letter w/ iron status) 82 -0.07 (-0.24, 0.10) 1.35 (0.71, 2.58) 
2 (control letter) 93 -0.07 (-0.23, 0.10) 1.68 (0.95, 2.97) 
3 (38 mg iron pill) 66 0.03 (-0.15, 0.21) 1.50 (0.82, 2.71) 
4 (19 mg iron pill) 51 0.06 (-0.13, 0.24) 1.55 (0.89, 2.71) 
5 (placebo pill) 45 Ref Ref 
Gender (N, %)    
Female 161 -0.05 (-0.16, 0.07) 1.37 (1.06, 1.79) 
Male 176 Ref Ref 
Age (mean, SD)    
< 30 15 0.00 (-0.29, 0.29) 1.33 (0.75, 2.38) 
30–39 25 0.11 (-0.12, 0.35) 0.50 (0.15, 1.72) 
40–49 54 Ref Ref 
50–59 112 0.06 (-0.11, 0.22) 1.20 (0.75, 1.94) 
≥60 131 0.05 (-0.11, 0.21) 1.23 (0.76, 1.99) 
Weight (mean, SD)    
< 150 lbs 60 0.10 (-0.06, 0.26) NA** 
150 – 174 lbs 80 0.01 (-0.12, 0.15) NA** 
175 – 199 lbs 84 Ref NA** 
200 or more lbs 108 0.08 (-0.05, 0.21) NA** 
Baseline lab values    
Anemia at baseline 45 -0.05 (-0.20, 0.10) NA** 
No anemia at baseline 291 Ref NA** 
    
Baseline Ferritin (ng/ml)     
Ferritin ≥ 26 ng/ml  116 Ref NA** 
Ferritin 12 to 25 ng/ml 124 0.01 (-0.11, 0.13) NA** 
Ferritin < 12 ng/ml  97 -0.01 (-0.16, 0.14) NA** 
    
Change in body iron  
(per mg/kg)  
 0.01 (-0.01, 0.02) 1.01 (0.99, 1.04) 
    
Fatigue at baseline 75 0.36 (0.25, 0.48) 4.55 (3.27, 6.32) 
No fatigue at baseline 262 Ref Ref 
Table 3.4. Adjusted models for change in Fatigue Score and Fatigue at Final Visit 
*Risk ratio, 95% Confidence Interval for Risk ratio 
+ Using linear regression. 
++ Using modified Poisson regression with generalized estimating equations. 
** Variables excluded from logistic model to ensure model convergence. 
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 To assess whether the loss to follow up may have varied by both iron status and 
levels of fatigue, we repeated the multivariate analysis using weights for each subject 
based on the inverse probability of being censored. Including both enrollment and interim 
visit data in modified Poisson regression with generalized estimating equations, the most 
important predictor of study completion, by far, was treatment assignment. As suggested 
by Table 3.1 and reported elsewhere,43 many subjects expressed dissatisfaction with long-
term use of a pill of unknown iron content, in many cases reporting they specifically 
desired (or were counseled by medical providers) to take iron. The final model selected to 
create weights included treatment arm, female sex (RR 0.84, 95%CI: 0.75 – 0.95) and 
baseline ferritin (RR for ferritin < 12 vs > 26 ng/ml (1.21, 95% CI: 1.06–1.39) and, 
hence, did not depend on any data from the interim visits. As seen in Table 3.5, the 
multivariate analysis using weights for censoring continued to support only baseline 
fatigue as a predictor of changes in Fatigue Score (0.36, 95% CI 0.20 – 0.52) and baseline 
fatigue (RR 4.78, 95% CI: 3.38–6.76) plus female sex (RR 1.37, 95% CI: 1.02–1.84) as 
risk factors for fatigue at study conclusion.   
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Category N = 337 Change in Fatigue 
Score+ 
(95CI)* 
Fatigue at Final 
Visit++ 
(RR, 95CI)* 
Grp Assignment     
1 (letter w/ iron status) 82 -0.08 (-0.23, 0.90) 1.27 (0.66, 2.43) 
2 (control letter) 93 -0.07 (-0.22, 0.08) 1.53 (0.89, 2.63) 
3 (38 mg iron pill) 66 0.02 (-0.14, 0.18) 1.57 (0.86, 2.89) 
4 (19 mg iron pill) 51 0.06 (-0.10, 0.23) 1.59 (0.94, 2.69) 
5 (placebo pill) 45 Ref Ref 
Gender (N, %)    
Female 161 -0.05 (-0.17, 0.06) 1.37 (1.02, 1.84) 
Male 176 Ref Ref 
Age (mean, SD)    
< 30 15 -0.01 (-0.29, 0.26) NA** 
30–39 25 0.08 (-0.15, 0.32) NA** 
40–49 54 Ref NA** 
50–59 112 0.03 (-0.13, 0.20) NA** 
60+ 131 0.03 (-0.13, 0.19) NA** 
Weight (mean, SD)    
< 150 lbs 60 0.14 (-0.03, 0.30) NA** 
150 – 174 lbs 80 0.03 (-0.10, 0.17) NA** 
175 – 199 lbs 84 Ref NA** 
200 or more lbs 108 0.09 (-0.04, 0.22) NA** 
Baseline lab values    
Anemia at baseline 45 -0.05 (-0.20, 0.10) NA** 
No anemia at baseline 291 Ref NA** 
    
Baseline Ferritin (ng/ml)     
Ferritin ≥ 26 ng/ml  116 Ref NA** 
Ferritin 12 to 25 ng/ml 124 0.02 (-0.10, 0.13) NA** 
Ferritin < 12 ng/ml  97 -0.03 (-0.18, 0.12) NA** 
    
Change in body iron  
(per mg/kg)   0.01 (-0.01, 0.02) 0.98 (0.96, 1.01) 
    
Fatigue at baseline 75 0.36 (0.24, 0.48) 4.78 (3.38, 6.76) 
No fatigue at baseline 262 Ref Ref 
Table 3.5. Adjusted models for change in Fatigue Score and Fatigue at Final Visit weighted 
for inverse probability of censoring 
*Risk ratio, 95% Confidence Interval for Risk ratio 
+ Using linear regression with GEE 
++ Using modified Poisson regression with GEE 
** Variables excluded from logistic model to ensure model convergence. 
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Discussion 
The STRIDE study’s primary aim was to evaluate operationally feasible 
approaches for reversing iron deficiency in blood donors, and it found that low- and 
medium-dose iron were equally effective and that providing donors recommendations 
based on their own iron status was also successful.43 This ancillary study sought to 
determine whether self-reported fatigue improved and whether those improvements were 
associated with improvements in iron status. The primary finding here is a lack of 
evidence that iron status is associated with fatigue either on a cross-sectional basis (at 
baseline) or in longitudinal follow-up in this population. Although meaningful increases 
in body iron stores were observed, and many donors had a sizable increase or decrease in 
their Fatigue Score, the latter measure was unassociated with iron status or changes 
thereto in any analysis.  This held true for analyses assessing for effect modification by 
baseline iron status or by baseline fatigue, and also adjusting for loss to follow up with 
inverse probability of censoring models. 
 In contrast, being female and having anemia at study enrollment were associated 
with a 50% greater risk for fatigue at baseline, controlling for demographic and donation 
frequency factors. Females continued to have modestly higher risk for fatigue at study 
conclusion, but fatigue at baseline was associated with a more than 4-fold risk for fatigue 
at study end. The finding of females being more likely to report fatigue is consistent with 
other reports,38  while the association with anemia is widely understood to be associated 
with the biological mechanism of reduced oxygen transport.35  Several investigators have 
reported improvement in fatigue levels in studies of non-anemic, iron-depleted women 
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following a course of iron therapy,6,41,55,66 but those results may not extrapolate to blood 
donors who are documented as having higher levels of health than the general 
population.5  
 The extent to which donation-induced iron depletion causes or exacerbates fatigue 
in blood donors independent of iron deficiency anemia is poorly understood, and is 
challenging to investigate. The voluntary nature of donation means that the only 
individuals who are easily evaluable are those who have chosen to present to donate at a 
blood center or a mobile blood drive. The health history questionnaire administered to 
blood donors does not directly elicit information on fatigue, with the closest inquiry being 
“Are you feeling healthy and well today?”3 The 1% of male donors and 14% of female 
donors who fail to pass the hemoglobin screen have increased risk for also being iron 
deficient, but many such donors fail to return and are consequently unavailable for further 
evaluation.27,45  
 Of the relatively few studies of fatigue conducted in blood donors, the results are 
mixed. One study found fatigue to be an uncommon phenomenon in blood donors and 
not associated with improvements in iron stores following use of oral iron.67 Another 
concluded that iron administration in non-anemic donors reduced fatigue by more than 
half, reported by 70% of subjects at study inception.49 However, this study had no control 
population and experienced heavy loss to follow up. Another study in the Netherlands 
estimated the incidence of fatigue at less than 2% in first-time blood donors,65 but 
collected no information on iron status, measured fatigue only once, and did not study 
repeat donors.  A large study in the US found 8% of 1000 blood donors contacted in the 
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weeks following blood donation reported fatigue onset immediately following donation 
but did not use a validated instrument and defined fatigue on the basis of a single binary 
question.47 Further, fatigue in the immediate post-donation period is thought to be due to 
loss of blood volume and the transient reduction in hemoglobin levels with recovery from 
donation. The physiologic underpinnings of transient fatigue may be different than 
fatigue elicited prior to the next blood donation several weeks later (see discussion 
below). Another large study, conducted among Danish blood donors, found no 
association between iron status and self-reported mental or physical quality of life 
measures, but only a single cross-sectional assessment was performed.52 
 Several potential explanations might account for our null result. It may be that 
clinically relevant fatigue was not present in many STRIDE donors, that the range of 
fatigue experienced by them was overly narrow, or that our instrument was insufficiently 
sensitive to changes experienced by the subjects. Evidence that the instrument was 
inappropriate for its intended purpose include the clear ceiling effects at enrollment and 
study end, and the average change of 0.0 in Fatigue Score for subjects completing 
STRIDE. Nonetheless, nearly one-half of subjects had a change in Fatigue Score of at 
least one-half the SD of 0.5. An increase or decrease greater than 0.25 represents a 
change of at least 3 points in the sum of responses to all 11 questions, which was 
identified as a minimal clinically important difference (MCID) by the developer of the 
scale which provided the large majority of questions for the survey used in STRIDE.18 
Another research group, however, estimated the MCID to be considerably larger at 10 
points,50 a magnitude of change experienced by fewer than 10% of STRIDE subjects. 
		
52 
Fatigue is an inherently subjective condition, and scales that are principally derived for 
clinical (often oncology) patients may perform differently in a population of healthy 
frequent blood donors. 
 Alternately, our measures of association might be biased by selection effects if the 
heavy dropout is related both to changes in iron status and to fatigue. Though dropout 
was strongly associated with treatment arm, which was itself associated with changes in 
iron status, there is little evidence for fatigue being a contributor to failure to complete 
STRIDE. The models predicting study completion did not indicate a clinically relevant 
association with baseline fatigue, and the multivariate assessment using inverse 
probability of censoring weights did not produce notable changes to the parameter 
estimates. Moreover, post-study review of blood center operational databases shows that 
most donors who discontinued participation in STRIDE continued to donate frequently 
following withdrawal from the study. Were fatigue the primary motivation for loss to 
follow-up, one might expect discontinuation from blood donation also to have resulted. 
It might be the case that selection effects of who enrolled in STRIDE made assessing the 
outcome of interest particularly challenging. Their average donation frequency of 7 units 
in the two years prior to enrollment8 and the average contribution of nearly 9 units (not 
shown) during the study period denotes them as an exceptionally productive group of 
donors. This contrasts with an average of 1.6 donations per year as assessed on a cross-
sectional basis4 and lower yet when measured longitudinally in an unselected blood donor 
population.59 Donors that experience clinically relevant fatigue following donation may 
be more likely to donate less frequently, or to discontinue donating altogether. Therefore, 
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the STRIDE population may be unrepresentative of other donors, as donors who do not 
experience fatigue despite multiple blood donation and associated iron depletion. The 
aforementioned study in the Netherlands65 found low incidence of onset of fatigue in first 
time donors, but those who experienced it had a sharply reduced return rate.  
 One potential unanswered question is whether the temporality of outcome 
ascertainment diminished our efforts to document fatigue and changes in fatigue in this 
cohort. The administering of questionnaires more than once contrasts with a large 
published study on fatigue in blood donors (also null),52 but if incident fatigue is a 
transient phenomenon following donation rather than an enduring manifestation, our 
approach would not have captured that adequately. To that point, the largest study 
conducted in the US, which telephoned 1000 donors roughly 3 weeks after donation, 
found 8% of them reporting fatigue as an adverse outcome, albeit on the basis of a single 
question.47 Similarly, a study in Sweden found that 10% of donors reported feeling tired 
following donation, with onset commencing shortly after their donation and with duration 
measured in days rather than weeks.58  Our design, or similar approaches that capture 
donors only after they have waited at least the minimum interval of 8 weeks between 
donations and have returned to donate, is at a structural disadvantage in trying to measure 
a short-lived effect. Additional evidence supporting this idea comes from a recent Dutch 
study involving more than 20,000 donors.64 In surveys mailed to donors shortly following 
donation, between 5 (males) and 9 times (females) as many donors reported lack of 
energy following their most recent donation compared to prior to having donated.  As 
discussed above, however, the physiologic basis for transient fatigue may be different 
		
54 
that that experienced weeks to months after blood donation, and is not likely to be related 
to iron depletion. Thus, although both symptoms may be characterized as fatigue, they 
may reflect fundamentally different mechanisms. 
 In conclusion, an array of logistical and methodological complexities introduces 
challenges in evaluating fatigue in blood donors and the causal role of blood donation and 
iron loss. The STRIDE study failed to find iron status associated with fatigue at study 
inception or its conclusion. Future efforts might benefit from a study population more 
diverse in its donation habits, including representation of first-time donors, and from 
assessments at multiple time points following the donation event itself. 
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CHAPTER FOUR: SIMULATING THE IMPACT OF MITIGATION MEASURES 
ON IRON STATUS AND BLOOD AVAILABILITY 
Introduction 
 More than 11 million units of red cells are transfused annually in the United 
States (U.S.),4,30 80% from donors with previous donations. Determining the iron status 
of blood donors is not required by regulation or professional standards, rarely performed, 
and not available as a point-of-care test. The prevalence of, risk factors for, and potential 
to mitigate iron depletion in blood donors have been assessed in multiple public forums 
over the last 15 years.20–22,29 Several viable options exist for effectively reducing the 
collection of blood from iron depleted individuals, but none without known or potential 
drawbacks. One strategy could require donors wait longer between donations than the 
current minimum inter-donation interval of 8 weeks, providing more opportunity for the 
donor to recover the iron lost in a donation.14  For many donors, however, that process 
may take 6 months or longer,40 a duration which applied across the board would seriously 
impair sufficiency of the blood supply.59 A second option would promote use of iron 
supplementation by blood donors, which accelerates the recovery of iron stores40 and is 
also associated with reduced exclusion for low hemoglobin, enhancing operational 
efficiencies.57  Only one large blood center in the U.S. directly provides supplemental 
iron to its donors,68 and even that program is targeted to a narrow slice of the donor 
population, premenopausal female donors who attempt multiple donations in a year and 
have a deferral for low hemoglobin. Concerns for adopting this measure include the 
complexity of understanding and addressing the wide array of pathological conditions 
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that might alter donor iron status aside from blood donation. Scant evidence exists to 
support the efficacy of less direct approaches for encouraging iron supplementation – 
such as enhanced educational efforts,28,60 with little rigorous assessment conducted to 
date. Finally, blood centers could implement testing for plasma ferritin, which is a 
measure of donor iron stores, and restrict donation eligibility for those found to have low 
iron.31 This approach has both direct and indirect financial impact, however, in the costs 
of performing the testing and the potentially lengthy periods during which iron depleted 
donors lose eligibility for donation. While perhaps not insuperable, these implications are 
not trivial in an era of declining reimbursement rates for transfused blood products and 
precarious sustainability of the blood supply.46  
 With the high prevalence of iron depletion in blood donor populations well 
documented, including most recently in high-school aged donors,22 pressure grows for 
taking action to reduce iron depletion.2 While scrutiny from governmental and 
professional standard-setting organizations has not yet led to new requirements that may 
be disruptive and costly, a robust assessment of the range of strategies under 
consideration will be useful for all stakeholders. A clinical trial could help elucidate the 
physiological and behavioral outcomes that follow any of the aforementioned strategies, 
but would require a very large number of donors observed for a long time and, hence, 
would accordingly be very costly. The modeling efforts reported herein draw on recently 
available data to examine the potential for improvements in donor iron status under 
alternate strategies, and at what possible cost to sufficiency of blood component 
availability. 
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Methods 
Study population 
The majority of model source data comes from the Retrovirus and Donor 
Evaluation Study-II (REDS-II) program sponsored by the National Heart, Lung, and 
Blood Institute (NHLBI). Six geographically-dispersed blood centers with 
demographically diverse donor populations participated in REDS-II, representing 
approximately 8% of the U.S. blood supply.4 The REDS blood centers systematically 
collected information including visit date, demographics, and visit outcome (donation of 
1 or 2 units of red cells, or alternately deferral for low hemoglobin or other reasons) from 
2006–09. Roughly 1.9 million unique donors contributed 6.1 million donor visits to the 
data set, representing donation of 5.1 million red cell components and more than 800,000 
deferral visits resulting in exclusion from donation, mostly for low hemoglobin.  
In addition, the REDS-II program conducted a longitudinal cohort study between 
2007–2009 on the iron status of blood donors, the REDS-II Iron Status Evaluation study 
(RISE).13–14 The RISE study provides additional source data for estimating the 
association between donor demographic, behavioral, and donation frequency factors and 
their iron status. These estimates were validated against published data from Canada,33 
which had equivalent donation eligibility criteria to the U.S. for the period from which 
REDS-II data were generated, and also from unpublished data. 
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Baseline model development 
 To assess the effectiveness of a series of scenarios to reduce iron depletion, we 
simulated a population of 50,000 blood donors (equivalent to that of a small US blood 
center) under various mitigation strategies. A Markov model was developed in TreeAge 
Pro 2017 (https://www.treeage.com) that represents a transition state model where 
individuals cycle among health states with user-specified probabilities and accumulate 
costs and outcomes during a determined number of cycles (Table 4.1, Figure 4.1). The 
model is stochastic at the individual level, but the simulated population is large enough 
that outputs converge to stable expected values. Hence, uncertainty is captured not by 
confidence limits around an estimated parameter but rather by the range of modeled 
interventions and by sensitivity analysis. Microsimulations allow for modeling of a 
heterogeneous cohort, required here given the considerable variability that exists across 
sub-groups of donors. Based on observations in REDS-II, a 2 to 1 ratio was assigned to 
donors for having made prior donations versus having first-time donor status. Visit 
frequency, outcome, and return behavior were customized for 8 subgroups each of first-
time and repeat donors, respectively, with four age groupings for each sex.  Model 
follow-up for each simulated donor was 5 years to allow for sufficient time for changes 
introduced into the modified models to be observed. The cohort was configured as a 
dynamic population with exit rates (for loss of eligibility or for failure to return) based on 
those observed in REDS-II by sub-group and with entry distributed evenly over the first 
year.   
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Variable description Type of variable Values Reference / Source 
Cohort for donor  
sub-group* 
Categorical 16 groups representing all combinations of sex, 4 
age groups, and first-time or repeat donor status 
Spencer (2016);  
see Table 4.2 and Table A.4.1 
Donor visit outcomes Point estimate Proportion of donor visits resulting in: 
Donation of 1 or 2 red cell units,  
Deferral for low hemoglobin, other temporary 
deferral, and permanent deferral 
Custer (2012), 
Spencer (2016);  
see Table 4.2 and  
Table A.4.1 
Donor visit intervals Probability 
distribution 
Estimated number of days waiting before return 
to donate following successful blood donation 
modified from Spencer 
(2016);  
see Table A.4.1 
Donor exit from 
population 
Point estimate Proportion of donors with failure to return to 
donate following donation or deferral 
Spencer (2016);  
see Table A.4.1 
Donor use of iron 
supplementation (IS) 
Point estimate Proportion of donors who use supplemental iron 
either in multivitamin or separate supplement 
modified from Cable (2016);  
see Table A.4.3 
Donor iron depletion Point estimate Proportion of donations made with donor in state 
of iron depletion, defined as ferritin < 26 ng/mL 
Cable (2012), 
REDS-III unpublished, 
Goldman (2017);  
see Table A.4.4 
Table 4.1. Baseline model inputs and assumptions 
* All other variables in table are tailored to cohort-specific source data. 
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Figure 4.1. Simplified model transitions 
A virtual cohort is established from assignment at first visit to a blood center, and cycles through a baseline 
scenario and alternate approaches. For baseline and alternate mitigation strategies, 50,000 subjects (user-
defined number) are assigned to the first-time or repeat donor cohorts in a 1:2 ratio. Reference tables for 
each cohort are used to assign one of eight profiles based on sex and age group. These profiles inform visit 
outcomes, donor iron status and iron supplementation determinations, and return probability and return 
intervals. 
 
The use of “clones” reduces model structure and risk of coding errors as updates to variable definitions get 
automatically distributed across all clones. 
 
 While the simulation program is designed for financial cost-benefit assessments, 
it can be tailored to evaluate alternate outcomes. The current effort does not include 
financial costs, and the primary outcomes of interest are the number of units of red cells 
collected over the observation period, and the number of units collected from a donor 
who was iron deficient at the time. The objective is to evaluate for each potential 
mitigation strategy how effective it might be in reducing iron deficiency in blood donors, 
		
61 
and at what potential impact to the supply of blood products. During model development 
the model was tested with a sample size of 10,000 “trials,” with each trial representing a 
simulated donor, who either completes the full 5-year period or drops out of the donor 
pool due to loss of eligibility or failure to return. Upon completion of the model, the 
number of simulated donors was systematically increased until outputs from serial runs 
showed minimal variability. This threshold was reached around 25 to 30 thousand 
donors. For final runs, the number of trials was increased to 50,000 to ensure stability of 
results and to provide a number representative of many small US blood centers.4 
Increases in sample size well beyond 50,000 were unnecessary given the interest in 
proportional changes rather than absolute numbers, and much larger numbers increased 
the duration of trial runs from several minutes to hours on a single computer. 
Determinations made at first visit 
 Upon entering the cohort at first visit, donors were assigned to either the first-time 
donor cohort or the repeat donor cohort, and within each they were further assigned to 
one of eight categories of sex and age group. These distributions were based on observed 
frequencies during REDS-II, where detailed prospective summaries of donor productivity 
and return behavior varied considerably by whether they had any prior donations (Table 
4.2, greater detail in Table A.4.1). Donors entering the repeat donor cohort were also 
assigned a prior donation frequency based on unpublished data (Table A.4.2), and a 
reference matrix of 730 daily columns (2 years) was developed to “seed” the number of 
prior donations in time. Hence, while both first-time and repeat donors were simulated 
prospectively for a 5-year period, the reference matrix provided a 2-year donation history 
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for repeat donors that allowed for time-dependent calculations of iron depletion based on 
dynamic counts of prior 24-month donation history (updated at each simulated donor 
visit).  At each donor visit, a person could have one of several outcomes: donation of a 
single or double unit of red cells or deferral for low hemoglobin or other cause. The 
probability of each event varied by donor sub-group and was drawn from probabilities 
based on REDS-II data (Table 4.2).27,59  Whether donors were using iron supplementation 
(IS) at the time of the donor visit was estimated (Table A.4.3; 20% overall with range 3 
to 45% across all sub-groups), as was the probability that they had iron depletion (ID) at 
the time (Table A.4.4; approximately 40% overall, range 10 to 94% across all sub-groups 
without adjustment for iron supplementation).  Whether a donor returns to donate 
following the first presentation is based primarily on REDS-II observations (Table A.4.1; 
52% return following visit 1, range 33 to 71% across all sub-groups) and the literature.54 
The timing of the next visit for those who do return is the largest number of days 
represented by the current minimum required interval of 8 weeks (baseline scenario), an 
alternate hypothetical extended minimum interval of 12, 16, or 26 weeks (for intervention 
strategies), and a probability distribution drawn from observed return intervals in the 16 
donor sub-groups following donation in REDS-II (Table A.4.5; median return interval 
119 days, range 105 to 163 days across all sub-groups). Details of donor transitions and 
model structure are given in Figures A.1a–A.1d. After results from the baseline scenario 
reflected donation rates approximating those observed in REDS-II, the potential 
mitigation strategies for reducing iron depletion were developed as modifications to the 
baseline parameters. 
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 Inputs based on REDS-II Outputs observed in simulation  
First-time cohort (FT) 
Females % of 
FT 
cohort 
% R1 % R2 % Hb 
deferral 
% 
Other 
deferral 
Ave. 
RC / yr 
  
N 
% of 
FT 
cohort 
Ave. 
RC / yr 
% ID 
donations 
≤ 20 yrs 35.1 78 0.5 18 3.5 0.69 5,912 35.6 1.01 52 
20–34 11.7 78 0.5 18 3.5 0.67 1,902 11.4 0.97 45 
35–49 8.1 78 0.5 18 3.5 0.77 1,359 8.2 1.14 45 
≥50 4.1 80 0.5 14 5.5 0.91 700 4.2 0.90 24 
Males           
≤ 20 yrs 27.0 85 8 1 6 0.87 4,361 26.2 1.12 29 
20–34 7.7 85 6 1.5 7.5 0.90 1,335 8.0 0.99 21 
35–49 4.4 86 6 2 6 1.07 754 4.5 1.14 24 
≥50 1.9 86 5 2.5 6.5 1.22 299 1.8 0.98 17 
 16,622  1.04 39% 
Repeat cohort (RPT) 
Females % RPT 
cohort 
% R1 % R2 % Hb 
deferral 
% 
Other 
deferral 
Ave. 
RC / yr 
 N % RPT 
cohort 
Ave. 
RC / yr 
% ID 
donations 
≤ 20 yrs 6.6 78 0.5 19 2.5 0.66 2,156 6.5 1.11 58 
20–34 12.3 78 1 19 2 0.83 4,055 12.1 1.24 55 
35–49 17.9 78 1 19 2 1.11 6,027 18.1 1.53 52 
≥50 14.7 80 1 15 4 1.36 4,881 14.6 1.17 33 
Males           
≤ 20 yrs 5.2 82 8 2 8 0.82 1,770 5.3 1.03 37 
20–34 9.6 82 6 3 9 1.13 3,275 9.8 1.05 30 
35–49 17.0 83 6 3 8 1.54 5,610 16.8 1.32 32 
≥50 16.7 83 7 4 6 1.78 5,604 16.8 1.42 30 
 33,378  1.29 41% 
Table 4.2. Cohort assignment, model inputs, and baseline simulation outputs based on 50,000 subjects over 5 years 
R1 = donation of one unit; R2 = donation of two units; Hb deferral is deferral for low hemoglobin; Ave RC/yr is Σ(RC units by group) / Σ (PT by 
group); % ID donations is estimated proportion of donations made in an iron-deficient state.
		
64 
Assessment of alternate iron mitigation strategies 
Three broad intervention strategies were developed for comparison to the baseline 
scenario, each with 3 variations relative to current regulations and practice. 
1) Iron supplementation: Blood donor consumption of supplemental iron is poorly 
understood both in terms of prevalence of the activity and motivations therefor. 
Recent evidence suggests that a small minority of blood donors—20%—report use 
of exogenous iron and that for the majority of them the most frequently cited 
motivation is general health and wellness as opposed to supporting their fitness for 
blood donation.16 This indicates there is considerable room for blood centers to 
fortify their efforts to promote iron supplementation. Modeled strategies include 
enhanced education, distribution of coupons for iron supplements, and direct 
distribution of pills to donors upon successful completion of a donation procedure. 
These strategies are simulated as increasing the proportion of donors taking iron by 
10 percentage points, 20 points, and 40 points, respectively. The empirical evidence 
for blood center measures to promote iron supplementation in donors is lacking, and 
these numbers are considered as representing reasonable upper bounds of a 
successful intervention. For example, with education, the proportion of first-time, 
young male donors taking iron is assumed to increase from 3% (Table A.4.3) to 
13%, and in post-menopausal females donating more than 6 times in 24 months 
from 45% to 55%. To assess the impact of a generic intervention that increased the 
entire donor pool to various levels of iron supplementation, we performed 
sensitivity analysis where 50 and 75% of all donors were assumed to be taking iron. 
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The baseline reduction in risk for ID for those taking iron is estimated as 35% 
reduced risk, and this parameter is also subjected to sensitivity analysis over a range 
of 25 to 55% reduction in risk.14,43 
2) Extended interdonation intervals: Extending the minimum interval between 
donations from the current 8 weeks to 12, 16, and 26 weeks was assessed. In the 
baseline scenario, time to the next visit is based on a probability distribution derived 
from return intervals observed during REDS-II (Table A.4.5) for the donors who 
returned following their first visit. For alternate scenarios the longer of the new, 
hypothetical minimum or the return interval drawn from the probability distribution 
is used. For example, we would expect almost 70% of the return intervals by first-
time male donors ≤ 20 years old to be unaffected by a 16-week interval, in that the 
30th percentile of return intervals in that groups is 114 days.  
3) Ferritin testing: A test of the concentration of ferritin in serum or plasma samples 
provides a direct measurement of an individual’s iron stores. Developed 40 years 
ago,26 ferritin testing has not been widely adopted by blood centers outside of a 
research setting. The hemoglobin screening performed as part of donor eligibility 
determinations is recognized as a poor indicator of iron status, at best an indirect 
and lagging indicator. Ferritin testing was alternately modeled as applying to target 
groups known to be at higher risk for iron depletion, and to all donors. The former 
includes females of childbearing age,14 young donors,22 and “frequent” donors of 
either gender, generally twice per year for females or three times for males.14 Given 
the dynamic nature of blood donor populations, the proportion of donors who meet 
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this definition of “frequent” donors is not well-characterized. The model’s time-
dependent tracking allows for derivation of this calculation, based on donations 
occurring during the 5-year period simulated and, for repeat donors, the 2-year prior 
donation history developed at their entry into the cohort. One approach models risk-
group testing based only on demographic factors (young donors, defined as ≤ 20 
years of age, and premenopausal females, defined as < 50 years old), and another 
tests these groups along with those meeting the definition of “frequent” donors. A 
third simulation tests every donor following a successful donation. Donors with a 
ferritin test result < 26 ng/mL are assigned a minimum donation interval of 26 
weeks prior to their next visit. Similar to the Extended Intervals approach above, if 
a return interval longer than this minimum is drawn from the probability 
distribution, then the actual return interval used in the model is not affected by the 
ferritin testing.  While in practice notification of low ferritin results will almost 
certainly be accompanied by recommendations to take supplemental iron in 
consultation with their medical provider, that combination is not included here. 
Results 
 Both summary data and data disaggregated by cohort indicate the baseline model 
performs in a satisfactory manner.  Table 4.2 shows that the intended 1:2 ratio of First-
Time to Repeat donors was observed for the 50,000 subjects run through the 5-year 
baseline scenario. Similarly, the proportion assigned to each cohort’s 8 age-sex strata 
closely tracks that observed in the REDS-II donor population. The primary metric of 
donation intensity—the sum of red cell units collected divided by the sum of person-
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time—is very consistent at the aggregate level between model simulations and REDS-II 
inputs. The overall average of 1.21 units per donor per year (average of 1.04 in First-
Time and 1.29 in Repeat cohorts) derived from the simulations (Table 4.2) is only 7% 
higher than that observed in REDS-II (Table A.4.1). The variability across groups is not 
identical between the two, but general patterns mostly held (higher productivity in Repeat 
than in First-Time donors and in males compared to same-aged females). These results 
were deemed a close enough approximation to undertake evaluation of the various 
alternate scenarios.  The prior 2-year trailing donation history at first presentation in 
Figure 4.2a using unpublished data of unselected donors and the cumulative 5-year count 
of units derived from the simulations in Figure 4.2b both show the limited, short-term 
engagement by many donors with their blood center.  
 
Figure 4.2a. Source data for simulation model: distribution of prior donation history at 
presentation to donate. 
0 = First-time donor. 
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Figure 4.2b. Output from simulation model: cumulative donation frequency over 5 year 
follow-up. 
0 = donor who exits donor pool prior to making a successful donation (deferred at all 
presentations). 	
Though no published assessment of iron deficiency in an unselected U.S. donor 
population exists, the baseline scenario suggests that approximately 40% of blood 
donations in the simulation come from donors with iron depletion (Table 4.2). The multi-
year follow-up provides sufficient time for the aggregate proportion of donations from 
iron-deficient donors in the first-time donor cohort to approach, but not quite converge to 
that in the repeat donor cohort (39 vs. 41%). The results in Table 4.3 provide the number 
of estimated donations, red cell units, and donations made by an iron-depleted donor 
under each scenario. The proportion of donations given by a donor with ID is derived, 
and absolute and relative changes in that proportion are also calculated. The percentage 
change in estimated red cell units collected from the baseline to the alternate scenario is 
also derived.
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N red cell 
units  
% Δ in red 
cell units 
N 
donations  
N 
donations 
with Iron 
Depletion 
% 
donations 
with ID 
Absolute 
change  
% donations 
with ID 
Relative 
change  
% donations 
with ID 
Baseline 271,650 NA 261,461 105,272 40.3 NA NA 
Pr
om
ot
io
n 
of
 
Ir
on
 
Su
pp
le
m
en
ta
tio
n Education adds 
10% to all donors 
271,650 0 261,461* 101,340 38.8 -1.5 -3.7 
Coupons + 20% 
points 
271,650 0 261,461* 97,435 37.3 -3.0 -7.4 
Pills + 40% points 271,650 0 261,461* 89,403 34.2 -6.1 -15.1 
E
xt
en
de
d 
In
te
rv
al
  f
or
 a
ll 
do
no
rs
 
12 weeks 262,420 -3.4 252,482 99,815 39.5 -0.7 -1.8 
16 weeks 252,558 -7.0 242,905 91,238 37.6 -2.7 -6.7 
26 weeks 214,937 -20.9 206,791 48,776 23.6 -16.7 -41.4 
Fe
rr
iti
n 
te
st
in
g 
+ 
26
-w
ee
k 
in
te
rv
al
  
if 
ir
on
-d
ep
le
te
d 
Young donors, 
females < 50yo 
257,549 -5.2 247,707 87,827 35.5 -4.8 -11.9 
Same, also 
“frequent” donors 
255,161 -6.1 245,466 84,636 34.5 -5.8 -14.4 
All donors 252,076 -7.2 242,525 81,271 33.5 -6.8 -16.8 
Table 4.3. Interventions modeled and change from baseline scenario for trials with 50,000 subjects 
* For IS, taking iron is not expected to change donation return intervals and hence has no change on collections. 
For IS, the specified number of percentage points is added to baseline assumptions about IS usage (Appendix Table A.3.3).  
For Ferritin, the first 3 age groups of females (< 20, 20–34, 35–49 years) and the youngest males (< 20 years) are tested in the age*sex scenario. 
Frequent donors are female donors with 2 and male donors with 3 donations over the prior year at the time of presentation.
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Overall, no strategy on its own reduces by half the proportion of donations given 
by iron-depleted donors. Only extending the minimum interval to 26 weeks provides a 
large reduction in the % ID donations, with a 41% drop in the baseline proportion, but 
nevertheless only to just under a quarter of all donations. Unfortunately, that sizeable 
improvement comes at the cost of 21% of the blood supply. Ferritin testing, even limited 
to females of childbearing years and to young donors, achieves at least a double-digit 
drop in the proportion of donations made by iron-depleted donors. The impact on 
collections from the 26-week interval applied to donors with ID is a fraction of that 
compared to 26-week intervals applied across the board, but erasing a 5 to 7% gap in 
blood collections is a formidable challenge for any blood center.  Increases in donor use 
of iron supplementation only exert a relatively strong impact with direct distribution of 
pills to donors (15% relative decline in ID), where the 40-percentage point gain across 
the board would bring the population average to approximately 60% practicing IS. 
Sensitivity analyses based on the assumed IS efficacy of 35% reduction in risk for ID 
shows that at 90% coverage in the donor population, 28% of donations would still come 
from iron-depleted donors (Figure 4.3a). Under more realistic assumptions of 50 to 75% 
of the donor population taking iron, the estimate proportion of donations from iron-
depleted donors ranges from 25 to 30% even with presumed efficacy as high as 55% 
lower risk (Figure 4.3b). 
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Figure 4.3a: 1-way sensitivity analysis: estimated proportion of red cell donations made by 
iron deficient donor assuming up to 90% of donors are using iron supplementation. 
 
 
 
Figure 4.3b: 2-way sensitivity analysis: estimated proportion of red cell donations made by 
iron deficient donor assuming 50 or 75% of donors are using iron supplementation (pIS) 
and with efficacy ranging from 25 to 55% in reducing risk for ID. 
		
72 
Discussion 
Blood collectors in the U.S. face a widely-recognized problem of a high 
proportion of donations coming from donors who are in a state of iron depletion.20–22,29 
The optimal solution for any given blood center might differ based on size, setting (rural 
vs. urban) and other logistical considerations, but each strategy will impose some amount 
of direct costs, and quite likely indirect costs tied to replacing the donations foregone as a 
result of new procedures. This study seeks to model the magnitude of changes that might 
follow the strategies under strongest consideration by most blood centers and specifically 
endorsed in industry bulletins.1,2 Though financial considerations will be part of each 
blood collector’s decision-making process, the key outputs from these simulations are the 
estimated impact on blood collections (e.g., the proportion of units needing to be made up 
to maintain a stable blood supply) and the change in the expected proportion of blood 
donations given by a donor who is iron deficient. Our primary finding is that most of the 
iron deficiency in blood donor populations is not curable by any of the modeled 
interventions. With an estimated percentage loss of blood collections in the low- to mid-
single digits for many strategies, the corresponding decline in iron deficient donors is of 
unexpectedly limited magnitude. Aside from the 41% decline in the share of donations 
given by iron deficient donors predicted by extending the interdonation interval to 26 
weeks, the other 8 strategies were associated with a 2 to 17% drop in donations from iron 
deficient donors. The former approach, however, comes at an estimated cost of 21% 
fewer donations from the existing donor pool. These results suggest the depth and 
complexity of the challenge of preventing iron depleted donors from giving blood while 
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maintaining sufficient supplies for the patients in need. 
As expected, the “cost-benefit” profile of targeting high-risk groups for ferritin 
testing was superior to that of applying a longer 12- or 16-week interdonation interval to 
all blood donors. The longer intervals are associated with a projected loss of blood 
products from 3.5 to 7%, respectively, but an estimated decline in donations from iron 
deficient donors of only 2 to 7%.  In contrast, ferritin testing plus an extended interval 
targeted to young donors, females < 50 years old, and frequent donors leads to an 
estimated loss of units collected of 6% but with an attendant improvement of 14% in 
donations from iron deficient donors. Extending ferritin testing to all donors is projected 
to gain another 2 percentage points of improvement (decline in ID donations) and 1 
percentage point of additional loss of units of blood. This limited benefit from testing the 
iron status of all donors, though favorable by comparison to doubling the interdonation 
interval to 16 weeks, results from the unavailability in the U.S. of an approved point-of-
care ferritin test that can be performed during blood donor eligibility screening. Under the 
current regime of performing ferritin testing after a completed donation, the proportion of 
donations from iron deficient donors will by definition never drop below the prevalence 
of iron depletion in first-time donors. Based on the respective contributions of new and 
established donors, one should expect the overall proportion to be closer to the higher 
prevalence in the repeat donor population.  
The inability to determine iron status of a donor prior to a donation, without 
scheduling a separate visit solely for that purpose, undermines just as powerfully the 
efficacy of enhanced promotion of iron supplementation. In the HEIRS study, daily use 
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of 38mg of oral iron sharply accelerated recovery of ferritin following a donation.40 In 
donors whose baseline ferritin was < 26 ng/mL, those taking iron recovered to baseline 
levels approximately 5 months faster than those not taking iron (median recovery time of 
21 days vs. > 168 days, after which time follow-up was discontinued), and recovery to a 
minimum level of 26 ng/mL was also faster (120 vs. > 168 days). In the group with 
baseline ferritin > 26 ng/mL, subjects assigned to take supplemental iron recovered on 
average a minimum of 2 months more quickly (107 vs. > 168 days). These time frames, 
together with the median return interval of 17 weeks (Table A.4.1) observed for all 
REDS-II donors, would suggest that broadly expanded use of supplemental iron in blood 
donors might considerably lower the prevalence of iron depletion at the time of donation. 
Here we have modeled interventions that increase by 50%, 100%, and 200% the 
proportion of blood donors taking supplemental iron (adding 10, 20, and 40 percentage 
points to the baseline 20%), but the decline in the proportion of blood donors with iron 
depletion at the time of donation only drops by 4 to 15%. This finding derives at least in 
part from the fact that under the most optimistic scenario fewer than half of first-time 
donors would be practicing iron supplementation, and from the inability of daily iron to 
keep some of the most frequent donors above a ferritin level of 26 ng/mL.43   
The expected impact on collections from expanded iron supplementation 
represents a particularly complex challenge. As developed, the simulation model 
determines the likelihood of a given donor’s use of supplemental iron following 
assignment of the outcome of their presentation to visit. That is, whether a person donates 
or is deferred for low hemoglobin, is not altered by use of supplemental iron, which is 
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consistent with neither tuition nor empirical observation.43,57 One should expect increased 
use of iron by donors to lower deferrals for low hemoglobin and lead to a corresponding 
increase in units collected.  Potentially offsetting this benefit, however, is the 
disincentivizing effect that stronger messaging might have on donors.  If told that they 
would optimally maintain fitness for regular blood donation only by taking iron pills, 
some donors might decide to donate at a lower frequency or to discontinue donation 
altogether.  There is almost no data to inform the existence or strength of such an effect, 
however. A large study in Canadian donors has found a decline in units collected of one 
unit per year in donors advised that their ferritin was low and provided additional 
counseling messages, but the follow-up period is relatively limited. Hence, while the 
current estimates of no change in collections with expanded iron supplementation is quite 
likely artifactual, there is reasonable basis to think the direction could be either positive 
or negative.  
The approaches evaluated here all have an empirical or biological basis for 
assumed efficacy, but none on its own comes close to eliminating the majority of 
collections from iron-depleted donors. Combinations of strategies will likely be required 
to approach acceptable yardsticks for success, albeit at cost of greater complexity, cost 
and potentially loss of blood units. At least one of the modeled approaches should be 
feasible at most blood centers, even if no strategy emerges as uniformly superior to the 
others. In any case, while any future change in regulations or industry standards may lead 
to a cascade of responses from blood centers and blood donors alike, the results presented 
here should be reasonable estimates of the direction and relative degree of change in 
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impact on ID and on blood collections across the alternate strategies evaluated. It is 
possible that full assessment can only be performed once financial costs are explicitly 
embedded in the simulations, but this is outside the scope of the current effort. 
As with any modeling effort, limitations include the inherent simplification that 
must be applied to model inputs, especially to those regarding donor return behavior. 
Individual decisions about whether and when to donate blood reflect an array of factors, 
including how well one feels physically, convenience, blood center recruitment, and 
intangible factors such as the subjective interpretation of staff treatment at recent or prior 
donation visits. Most of these variables are not measured by blood centers and are 
ignored in the models under development; however, blood availability estimates are 
highly sensitive to assumptions about return behavior.  
 Additional simplifications in model inputs reflect compromises between model 
efficiency, availability of inputs, and an interest in not producing results that are overly 
tailored to the six blood centers contributing the primary inputs. While these six blood 
centers represent both east and west coasts and 3 additional states in the northern US, 
there is no representation of the southwestern US. One such consideration regarding 
simplifications in model development is omitting race and ethnicity in forming the 
cohort. Though African-Americans have a lower range of hemoglobin than Caucasian 
populations,7 and are accordingly at much higher risk for exclusion from donation, most 
blood center populations have low representation of racial minorities. Further, the data to 
reliably estimate iron status in racial minority blood donors are not available.  
Independent of hemoglobin levels, race is associated with visit outcomes in other ways.  
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Asian donors have considerably higher rates of exclusion compared to other groups, and 
African-American donors have a rate of unsuccessful phlebotomy procedures twice that 
of the overall average of 5%.27 To the extent that our results for “average” sub-groups 
based on age, sex, and prior donation history are driven largely by Caucasian donors, 
they may not apply as fully to blood centers whose populations are more 
demographically diverse. An additional limitation is the omission from model inputs of 
donor weight or body mass. These factors are positively correlated with overall volume 
of blood and the ability to donate without becoming anemic or iron-depleted, but may 
only partially be controlled for in the donor groupings by age and sex.14,59 Finally, the 1:2 
ratio of First Time to Repeat donors in forming the simulation cohort mirrors both REDS-
II59 and cross-sectional characterizations4 of the national donor populations, but over a 5-
year period would undercount the proportion of donations from first-time donors, and, 
accordingly, overestimate the  proportion of donations given from an iron deficient 
donor. A more complex approach with ongoing donor entry to the simulation cohort 
would be expected to lower the estimated proportion of donations coming from iron 
deficient donors from 40% to roughly 37%. 
A final limitation is the limited availability of published data against which to 
validate our estimates of prevalence of iron depletion in a US donor population. The 
REDS-II RISE study which provided much of the operating data for the model enrolled 
from opposite ends of the donation frequency spectrum, assembling cohorts of first-time 
and frequent donors.14 As such it omitted a large number of blood donors in the national 
donor pool who are not first-time donors but do not donate frequently. While the overall 
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estimate of 40% of donations coming from iron-depleted donors may seem exaggerated 
(37% adjusting for ongoing donor entry), it is squarely in line with estimates from a large 
study recently completed in Canada.33 In that study, conducted in unselected donors from 
the overall donor population but subject to the same donation eligibility criteria as REDS-
II donors, 55% of female donors and 35% of male donors were found to have low ferritin, 
defined as less than 25 ng/mL. Another piece of evidence supporting our high estimates 
of ID in donors and the limited impact of the various strategies comes from the STRIDE 
study, which enrolled frequent donors who over a 2-year period gave more intensively 
than the average US donor appears to do.43 In groups assigned to take pills containing 19 
or 38 mg of iron for 56 days following each donation, at the conclusion of the study the 
prevalence of ferritin < 26 ng/mL ranged from 32 to 39%.43 On balance, our estimates of 
ID under the baseline scenario and for changes that may follow the interventions assessed 
here seem eminently plausible. The ability to sharply reduce ID in blood donors under 
real-world conditions may not be intractable, but there are considerable constraints and a 
sizable tradeoff in terms of blood availability. 
 In sum, these simulations, and further developments to them in the future, should 
help delineate which approaches for mitigating iron depletion in blood donors are likely 
to enjoy success, under what range of parameters and with the most limited impact on 
blood collections as possible.  
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CHAPTER FIVE: CONCLUSION 
 
 Even while the adverse consequences of iron depletion without anemia remain 
poorly documented, the blood collection industry in the United States is dedicating 
considerable resources to lowering the risk for iron depletion in its donor population. In 
part, this is driven by new results that point to a higher risk for iron depletion in teenage 
donors, who may in addition be at higher risk from low iron due to the neurocognitive 
maturation they are still undergoing and the importance of iron for myelination of nerve 
fibers. As a consequence, many blood collectors are developing measures expected to be 
implemented first for teen donors that will eventually be expanded to other at-risk 
populations.  
As this dissertation goes to press, an expert committee has been convened by 
industry regulator AABB (formerly the “American Association of Blood Banks”) to 
make recommendations on what measures should become minimal standards for blood 
center accreditation. This author is part of that effort and fully expects meaningful 
changes to take place in the ensuing years. The first analysis presented here provides 
counterevidence to the widespread perception that the rate of absorption of dietary iron is 
overtaken by the physiological stress of multiple donations and offers limited if any 
protection. The second effort addresses in part the motivation for changes, by trying to 
better understand potential adverse outcomes associated with low iron. The simulation 
study is firmly on point to the needs of industry and the donors who provide selfless gifts 
of lifesaving blood. With an ever-increasing amount of data, and of understanding, 
progress should follow.  
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APPENDIX A2.1: DEVELOPMENT OF IRON COMPOSITE SCORE 
The iron composite score provides quantitative estimates of dietary heme iron 
consumption by weighting for frequency (0 to 14 times per week) and estimated iron 
content in mg/100g serving.  Self-reported consumption of several categories of animal 
proteins was captured at enrollment by a self-administered questionnaire adapted from an 
NIH Diet History Questionnaire.48 The instructions asked subjects to indicate how 
frequently over the prior twelve months they consumed each of the items in the 
checklist below. The first seven items are significant sources of dietary iron, particularly 
heme iron (found only in meat, poultry and fish), which is more readily absorbed and less 
subject to interference of absorption in the small intestine than non-heme iron (found in 
plants and iron-fortified foods).23  Dairy products are associated with interference of iron 
absorption and were modeled as a separate variable. 
 
 
Figure A.2.1: Food frequency checklist from RISE enrollment questionnaire 
Estimated heme iron content was extracted from the USDA National Nutrient 
Database, release 26,62 which provides iron content per 100g (a standard 3.5 oz serving ) 
and is accessible online. The table with iron content per 100g serving was downloaded 
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into Excel, and this 8000-item database was filtered one by one for all line items 
containing “liver,” “beef,” etc.  Any item containing the words “baby food” were 
excluded as were items with “liver” from the searches for beef, lamb, pork, chicken and 
turkey. The number of items remaining, the average iron content per 100g, and the 
chosen amount used for weighting by iron content are shown in the table below.  The 
number of evaluable items per category ranged from roughly 20 (liver and clams) to more 
than 1000 (beef). Mean and median values for heme iron content differed considerably 
only for clams, in which case an intermediate value was selected for weighting. The iron 
weightings ranged from 0.7 mg (other fish) to 8.9 (liver); the remaining 5 categories 
ranged from 1.0 to 2.3 mg. 
 
 Beef Liver 
Lamb, pork,  
chicken, turkey Clams 
Oysters, 
mussels, 
shrimp, 
sardines Eggs 
Other 
fish 
N items 1054 21 200 / 442 / 468 
/188 
24 14 / 2 / 17 / 3 61 222 
Mean Fe 
/100g 
2.3 8.6 2.4 / 1.3 / 1.1 / 
1.5 
1.6 4.9 / 5.3 / 0.7 / 
1.7 
2.2 0.9 
Med Fe 
/100g 
2.3 8.9 1.8 / 1.0 / 0.9 / 
1.1 
0.6 5.4 /5.3 / 0.7 / 
2.3 
1.9 0.7 
Decision 2.3 
mg 
8.9 
mg 
1.0 mg 1.1 mg 1.0 mg* 1.9 
mg 
0.7 mg 
Table A.2.1: Heme iron content in mg per 100g serving, USDA National Nutrient Database, 
release 26 
*Decision of 1.0 mg for category of oysters, mussels, shrimp, sardines over-weighted to iron content 
of shrimp due to US consumption more than 20 times greater than other items. 
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The possible range for the iron composite score ranges from 0 (no reported consumption) 
to 236.6 (twice or more per day for all seven items), as indicated below.   
 
 Never 
<1x/ 
Wk 1x 2x 
3–
4x 
5–
6x 
1x/ 
Day 
2x/ 
Day Multiplier 
Min 
value 
Max 
value 
Points for 
frequency 
0 0.5 1 2 3.5 5.5 7 14    
Liver (any 
kind) 
        8.9 0 124.6 
Beef          2.3 0 32.2 
Lamb, Pork, 
Chicken, 
Turkey  
        1 0 14 
Clams          1.1 0 15.4 
Oysters, 
Mussels, 
Shrimp, 
Sardines  
        1 0 14 
Other Fish          0.7 0 9.8 
Eggs          1.9 0 26.6 
RANGE OF SUMMARY VALUES 0 236.6 
Table A.2.2: Derivation of values used to determine iron composite score at RISE 
enrollment 
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APPENDIX A2.2. CRUDE AND ADJUSTED ASSOCIATIONS BETWEEN IRON 
COMPOSITE SCORE AND IRON STATUS AT FINAL VISIT 
 IDE RR (95% CI) 
AIS 
RR (95% CI) 
Iron Composite 
Score Group 
Crude RR, 
95% CI 
Adjusted RR, 
95% CI 
Crude RR, 
95% CI 
Adjusted RR, 
95% CI 
Tertile 1 1.16 (0.87, 1.54) 
1.03 
(0.76, 1.40) 
2.40 
(1.29, 4.48) 
2.25 
(0.99, 5.12) 
Tertile 2 0.96 (0.71, 1.30) 
0.89 
(0.65, 1.23) 
0.89 
(0.41, 1.91) 
0.95 
(0.37, 2.43) 
Tertile 3 Ref Ref Ref Ref 
Sex     
Male Ref Ref Ref Ref 
Female 1.79 (1.41, 2.28) 
2.08 
(1.50, 2.87) 
2.76 
(1.60, 4.75) 
2.75 
(1.33, 5.71) 
Age group     
Age< 30 0.89, (0.58,1.38) 
1.74 
(1.13, 2.68) 
1.53 
(0.68, 3.45) 
4.39 
(1.86, 10.32) 
30–49 Ref Ref Ref Ref 
50+ 0.88 (0.68,1.14) 
0.80 
(0.60, 1.06) 
0.98 
(0.55, 1.78) 
0.90 
(0.46, 1.79) 
Donation Frequency Prior 24 months    
1–3 Ref Ref Ref Ref 
4–6 1.83 (1.19,2.82) 
1.44 
(0.83, 2.49) 
1.97 
(0.86, 4.55) 
1.46 
(0.48, 4.45) 
7+ 2.28 (1.52,3.43) 
1.48 
(0.84, 2.59) 
1.88 
(0.84, 4.20) 
1.21 
(0.42, 3.51) 
Interval since 
prior donation     
Up to 12 weeks 3.76 (2.65 5.34) 
4.82 
(2.91, 8.00) 
3.42 
(1.71, 6.85) 
7.21 
(2.46, 21.15) 
12 to 24 weeks 1.88 
(1.28,2.78) 
2.10 
(1.23, 3.59) 
1.56 
(0.72, 3.36) 
2.31 
(0.74, 7.58) 
> 24 weeks Ref Ref Ref Ref 
Weight     
< 150 lbs 1.37 (1.05,1.78) 
1.00 
(0.74, 1.36) 
2.25 
(1.31, 3.88) 
1.29 
(0.60, 2.76) 
150–199 Ref Ref Ref Ref 
200+ 0.63 (0.46,0.86) 
0.77 
(0.53, 1.12) 
0.55 
(0.26, 1.17) 
0.97 
(0.41, 2.31) 
Use of 
supplemental iron     
Never take 1.33 ((1.02,1.74) 
1.51 
(1.18, 1.92) 
1.65 
(0.93, 2.93) 
2.25 
(1.28, 3.95) 
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Ever take Ref Ref Ref Ref 
Dairy 
consumption     
0 to 4 times / week Ref Ref Ref Ref 
> 4 times / week 1.11 (0.84, 1.47) 
0.99 
(0.75, 1.31) 
0.98 
(0.55, 1.73) 
1.11 
(0.62, 1.99) 
Iron level at 
baseline     
Ferritin 26 to50 
ng/mL 
1.74 
(1.33,2.27) 
1.28 
(0.97, 1.69) 
3.00 
(1.57, 5.70) 
2.41 
(1.18, 4.93) 
Ferritin > 50 
ng/mL Ref Ref Ref Ref 
Table A.2.3: Crude and adjusted associations between Iron Composite Score and iron 
status at final visit 
In multivariate analysis, adjacent levels of several variables were combined to ensure 
model convergence given the relatively small number of outcomes at final visit for AIS 
(n=55), allowing for comparable assessments for IDE and the analyses combining interim 
and final visits to final visits alone. Results above present the risks restricting the analysis 
to final visits, when AIS and IDE are measured for 98% of those completing the study. 
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APPENDIX A3.1. FATIGUE INSTRUMENT ADMINISTERED AT STUDY 
ENROLLMENT AND CONCLUSION 
 
The following questions were included in the enrollment and final visit questionnaires. 
Instructions were to circle a response without mention of a specific time period. 
 
Figure A.3.1: Fatigue instrument administered at study enrollment and conclusion 
 
 
Not at 
all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very  
Much 
I am easily fatigued 0 1 2 3 4 
I feel listless 0 1 2 3 4 
I have trouble starting things 
because I am tired. 0 1 2 3 4 
I have trouble finishing things 
because I am tired. 0 1 2 3 4 
I have energy 0 1 2 3 4 
I am able to do my usual activities 0 1 2 3 4 
I am interested in sex 0 1 2 3 4 
I am motivated to do my usual 
activities 0 1 2 3 4 
I am frustrated by being too tired 
to do the things I want to do 0 1 2 3 4 
I have to limit my social activity 
with friends and family because I 
am tired 
0 1 2 3 4 
I engage in leisure and 
recreational activities 0 1 2 3 4 
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APPENDIX A3.2. SUPPLEMENTAL FIGURES OF CHANGE IN MEAN 
FATIGUE SCORE 
 
 
Figure A.3.2a: Change in Fatigue Score for all donors at final visit 
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Figure A.3.2b: Change in Fatigue Score at final visit by sex 
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Figure A.3.2c: Change in Fatigue Score at final visit by baseline fatigue 
 
 
		
89 
APPENDIX A4.1. DETAIL OF SIMULATION INPUTS AND MODEL STRUCTURE 
Characterization 
at 1st visit during 
REDS-II 
 
Donors 
(N) 
RC 
components 
(N) 
% w/ 
Return 
Visit 
 
N Return 
Visits 
Median 
Return 
Interval 
> RC* 
Ave. 
RC / 
Yr** 
% 
Donate 
≥ 2x/yr+ 
% w/ Hb 
deferral 
 
N Hb 
deferrals 
FT Females 316,189 452,092 39.7 291,236  0.71   93,447 
≤ 20 yrs 185,265 259,184 41.8 161,729 22.3 0.69 8.5 21.2 52,262 
20–34 63,538 84,157 33.5 50,770 18.6 0.67 9.1 20.8 17,871 
35–49 43,766 66,898 38.5 47,717 18.0 0.77 12.5 25.5 15,844 
≥50 23,620 41,853 42.0 31,020 16.0 0.91 17.1 21.4 7,470 
RPT Females 612,509 1,727,560 58.9 1,586,528  1.05   305,846 
≤ 20 yrs 73,310 132,093 50.4 99,350 21.9 0.66 6.3 25.4 28,452 
20–34 166,630 349,839 50.7 280,639 18.7 0.83 10.6 23.5 65,289 
35–49 211,180 633,547 61.8 603,181 17.3 1.11 17.3 30.1 123,045 
≥50 161,389 612,081 67.6 603,358 15.3 1.36 24.4 27.2 89,060 
FT Males 232,164 419,514 38.0 195,676  0.92   2,702 
≤ 20 yrs 149,266 260,218 38.6 109,953 23.0 0.87 14.4 0.6 977 
20–34 44,852 77,997 33.4 36,822 17.9 0.90 15.8 0.7 391 
35–49 25,552 52,918 39.8 30,183 17.0 1.07 21.3 1.5 512 
≥50 12,494 28,381 44.5 18,718 15.0 1.22 25.7 4.4 822 
RPT Males 551,096 2,191,338 61.1 1,726,946  1.45   35,629 
≤ 20 yrs 59,136 131,110 45.4 67,562 22.0 0.82 11.4 0.7 556 
20–34 129,621 370,780 50.5 242,020 17.7 1.13 19.0 1.2 2,374 
35–49 189,047 806,038 64.5 642,022 16.9 1.54 28.5 3.0 9,108 
≥50 173,292 883,410 70.6 775,342 14.7 1.78 35.0 7.5 23,591 
Totals 1,711,958 4,790,504 52% 3,800,386 17.0 1.13 18.6 15.0 437,624 
Table A.4.1: Detailed characterization of REDS-II Donors at First Visit and Donation Productivity During 2006–2009 
* Ave. RC (red cell) Interval: For those with return visit following 1st appearance in REDS-II, median interval following RC donation in weeks 
** Ave RC / Yr: Σ(RC donations by group) / Σ (PT by group) 
+ % Donate > 2x/yr: For those with > 1 year follow-up time, % {Σ(RC donations) / Σ (PT)} > 2 
FT = First-time donor; RPT = Repeat donor
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Count of 
donated red 
cell units in last 
24 months 
Percent of all 
donors 
(N=6,500) 
Percent of 
repeat 
donors 
Min interval 
since last 
donation 
(days) 
Max interval 
since last 
donation 
(days) 
0 donations  24%    
1 14% 19% 56 730 
2 11% 14% 56 365 
3 9% 12% 56 243 
4 8% 11% 56 182 
5 7% 9% 56 146 
6 7% 9% 56 121 
7 6% 8% 56 104 
8 5% 7% 56 91 
9 4% 6% 56 81 
10 2% 3% 56 73 
11 1% 2% 56 66 
12 1% 1% 56 60 
Table A.4.2: Trailing donation intensity for repeat donor cohort 
 Since donation frequency is a strong predictor of a primary outcome, iron 
deficiency, as well as another predictor of iron deficiency, use of iron supplementation 
(IS), a distribution of prior donation activity was developed for the repeat cohort. Using 
unpublished data on 6,500 Caucasian donors, the proportion of presenting donors with 0 
to 12 donations in the prior two years was summarized. The proportions were mapped to 
exclude those with 0 donations (first time donors, and those with prior donations longer 
than 24 months ago, whose iron status is equivalent to first time donors).  A reference 
matrix was developed, with 730 columns representing each day in the two years prior to 
first presentation to donate in the model. The minimum interval prior to the start of the 
model is 56 days, and the estimated number of units for each subject were distributed 
randomly across the 730-day period subject to the constraints of minimum required 
intervals. For example, a donor estimated to have 1 donation in the prior two years had an 
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equal probability of that donation having occurred any time between 56 and 730 days 
before. 
 
 FT Donors 
(%) 
≤ 2 RCE / 24m 
(%) 
2–4 RCE 
(%) 
4–6 RCE 
(%) 
> 6 RCE 
(%) 
Female      
≤ 20 yrs 8 13 18 21 29 
20–34 11 18 24 27 36 
35–49 16 24 32 35 45 
≥50 16 25 32 36 45 
Male      
≤ 20 yrs 3 4 4 5 7 
20–34 6 7 8 8 11 
35–49 9 11 12 13 18 
≥50 16 18 20 22 28 
Table A.4.3: Estimated proportion of donors taking supplemental iron by age, sex, and 
donation frequency 
FT Donors = First-Time Donors 
RCE / 24m = Red Cell Equivalents in 24 months prior to current visit (Donation procedure collecting two 
units counts as 2; whole blood counts as 1). 
 
Data source: Very little quality data are available on blood donor practices vis-à-vis iron 
supplementation. Use of supplemental iron is neither required to be eligible to donate nor 
does it influence the intervals within which a successful donor may return, so collection 
of the data at donor intake is not performed. In the Connecticut Blood Services Region of 
the American Red Cross, all presenting donors have been systematically queried for iron 
supplementation practices since December 2015. A logistic regression model was 
developed predicting iron supplementation usage for more than 50,000 donation visits. 
Predicted supplementation use was output and summarized in an Excel pivot table by 
age, sex, and prior donation frequency.  
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 At first visit in the simulation, first time donors are assigned a probability of 
taking iron based on their sex and age group. Repeat donors are assigned a probability of 
taking iron based on those two factors plus assignment of prior donation frequency as 
drawn from a probability table (see Table A.4.2).  
 
 FT Donors 
(%) 
≤ 2 RCE / 24m 
(%) 
2–4 RCE 
(%) 
4–6 RCE 
(%) 
> 6 RCE 
(%) 
Female      
≤ 20 yrs 48 66 81 90 94 
20–34 39 57 75 86 91 
35–49 33 52 70 83 89 
≥50 18 32 51 68 78 
Male      
≤ 20 yrs 15 27 45 63 74 
20–34 10 19 34 52 65 
35–49 10 19 34 52 65 
≥50 10 19 35 52 65 
Table A.4.4: Estimated proportion of donors with iron depletion by age, sex, and donation 
frequency, assuming no iron supplementation 
FT Donors = First-Time Donors 
RCE / 24m = Red Cell Equivalents in 24 months prior to current visit 
 
Data source: There are no reported data from US blood centers on the prevalence of ID 
in a representative population. Parameter estimates for prediction of ferritin < 26 ng/mL 
were derived from the REDS-II RISE study and unpublished data,14 and were compared 
to Goldman, et al given the equivalent donor eligibility criteria for Canadian donors in 
that report as for US donors during REDS-II.33 
 The numbers shown above do not reflect adjustment for iron supplementation. 
The model reduces estimated risk for ID by 35% if the donor is projected as taking iron 
supplementation, and the risk is also adjusted down by 50% for donors whose last 
donation was more than 6 months earlier.
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 N p5 p10 p20 p30 p40 p50 p60 p70 p80 p90 p95 
FT Females             
≤ 20 yrs 145,086 61 68 85 108 133 160 195 239 337 418 577 
20–34 46,064 57 63 74 91 111 133 173 219 308 442 612 
35–49 43,570 56 63 71 88 106 130 168 210 295 410 574 
≥50 28,607 56 60 66 78 92 114 140 182 245 365 504 
RPT Females             
≤ 20 yrs 89,680 59 63 77 98 126 156 196 252 362 523 724 
20–34 258,717 57 63 72 89 109 133 173 222 320 479 665 
35–49 561,875 56 62 70 84 101 124 156 199 280 420 592 
≥50 566,029 56 59 65 77 91 111 133 175 238 365 521 
FT Males             
≤ 20 yrs 103,976 62 70 91 114 139 163 197 240 337 388 547 
20–34 34,825 57 63 72 89 107 127 160 198 279 395 560 
35–49 28,440 56 62 70 84 105 123 151 188 254 370 514 
≥50 17,370 56 59 64 77 91 112 131 169 224 362 455 
RPT Males             
≤ 20 yrs 64,539 60 64 80 104 128 156 194 241 348 491 683 
20–34 230,681 57 63 70 86 105 126 155 196 273 412 588 
35–49 610,428 56 62 69 82 98 119 142 182 245 371 540 
≥50 733,341 56 58 63 72 87 105 126 156 210 349 473 
Table A.4.5: Percentiles of return intervals (days) following red cell donation by age, gender, donation status in REDS-II 
FT = First-time donor cohort 
RPT = Repeat donor cohort 
p5, p10, etc represent the 5th, 10th, etc percentile of the distribution of return intervals (in days) following successful donation for each of the 16 groups. 
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Figure A.4.1a: Model structure showing baseline strategy and 9 alternate strategies through 
which subjects are cycled 
 The 9 alternate strategies represent 3 broad approaches with 3 gradations for each. 
Encouragement of iron supplementation (IS) ranges from educational efforts, to 
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distribution of coupons for iron pills, to direct distribution of pills to donors.  The 
minimum interval between donations is extended from 8 to 12, 16, and 26 weeks. Ferritin 
testing with intervals extended to 26 weeks for those with low ferritin can be applied to 
all donors, to risk groups based on demographic factors, or to risk groups based on 
demographic factors and donation frequency.  
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Figure A.4.1b: Model structure showing assignment to First-Time or Repeat donor cohorts 
at first cycle through the model. 
 At first visit, subjects get assigned to the First-Time (t_donor_type =1) or Repeat 
donor cohort and to one of eight sex- and age-based profiles (t_profile). The profile 
remains constant for a given subject as (s)he progresses through the model, either for the 
full 1825 daily cycles or until leaving the donor pool. That is, subjects do not “age” into 
the next age group during model runs, reflecting inputs for donor attributes and behaviors 
drawn from prospective characterization of REDS-II donors classified at their first visit.59  
The frequency with which a donor makes donations is an important predictor of a critical 
outcome, making a donation while in an iron-depleted state, so a history of prior donation 
behavior is developed for subjects assigned to the Repeat donor cohort. The metric 
commonly used in modeling of iron depletion in blood donors is often a count of number 
of units donated over the two years prior to making a presentation to donate,14 so a 
reference matrix of 730 columns is used to “seed” whether a donor had a donation or not 
on each day for the previous two years before cycle 1 of the model. The distribution of 
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counts of prior two-year donations was drawn from an unselected cohort of 6500 
Caucasian donors (unpublished data, see Table A.4.2). This distribution was found 
comparable to an extract of operational data from the Connecticut Blood Services Region 
of American Red Cross for all donors (not shown) and hence used unaltered.  The timing 
of prior donations was assumed to be randomly spaced over the two-year trailing period 
within the constraints of a minimum 56-day period between each donation (double-red 
cell procedures were ignored), but once determined each historical donation remains 
“fixed” in a given temporal position as required for subsequent calculations of 24-month 
donation history. 
 The timing of each subject’s first visit is determined from a uniform distribution 
from 1 to 365 days (year 1 of the 5-year model period). Each subject thus contributes an 
average of 4.5 years person-time. 
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Figure A.4.1c: Model structure showing range of outcomes for each subject visit 
 
The most common outcome following a donor’s presentation to donate is their being 
allowed to make a donation. Approximately 87% of donor presentations result in a 
donation, while 13% result in the donor’s exclusion from donation due to ineligibility, 
called a “deferral.”27 Most deferrals are temporary, and deferral for low hemoglobin is by 
far the most common cause for deferral, generally 50 to 60% of total deferrals at most 
blood centers. Permanent deferral for high-risk exposures (intravenous drug use, risk for 
variant Creutzfeld Jacob Disease, etc) are relatively rare, representing less than 10% of 
all deferrals. Those who donate typically donate a single unit of red cells in a whole 
blood donation, but the use of automated machines to draw two units in a single 
procedure has become more common. Double-red cell procedures represent roughly 7% 
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of all red cell collection procedures4 and, accordingly, more than 10% of all red cell 
components collected. 
 Risk for deferral for low hemoglobin is about ten times greater for female than for 
male donors,27 and the interest in and physiological requirements for double-red cell 
donation are more prevalent in male donors. Age and prior donation history are also 
correlates of outcomes following donor presentation at a blood center, and the model 
inputs showing the distribution of each outcome is shown in Table 4.2.  
 At each subject visit, a determination is made on whether the subject uses iron 
supplementation, was in an iron-deficient state, and whether and when (s)he returns to 
donate. For the 3 strategies representing ferritin testing of donors, whether the donor’s 
iron-deficient state becomes known to the blood center is also derived since knowledge 
of that outcome establishes a new minimum interval of 26 weeks prior to the next 
possible donation. 
 Use of iron supplementation is based on survey responses from more than 50,000 
donors in the Connecticut Blood Services Region of the American Red Cross,16 which 
shows wide variation by age, sex, and donation frequency (Table A.4.3).  
 Whether a subject is classified as iron deficient is determined by a predicted risk 
based on age, sex, and donation frequency (Table A.4.4), the accumulation and timing of 
donations made during the model period, and the determination on whether the donor is 
taking supplemental iron. Supplemental iron is estimated to reduce risk of iron depletion 
by 35%, and donations made at an interval longer than 6 months subsequent to the last 
one are estimated to reduce risk by 50%. 
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 Return behavior is determined by a combination of whether a subject returns to 
attempt to donate again and, if so, the timing of that attempt. Whether a subject returned 
following the first presentation was based on observed donor behavior during the REDS-
II program, with a failure to return ranging from roughly 30% in older males in the 
Repeat donor cohort to 66% in 20- to 35-year-old females in the First-Time donor cohort 
(Table A.4.1).59 For subjects who do return, the timing of the return visit was calculated 
as the maximum of the current regulatory minimum interval following a successful 
donation, a hypothetical longer interval (12, 16, 26 weeks), or a cohort-specific 
probability distribution based on 3.5 million donation intervals observed during REDS-II 
(Table A.4.5).  
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Figure A.4.1d: Model structure showing determinations made following each subject visit 
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